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1 INTRODUCTION 
 
1.1 Lipid Metabolism 
 
Lipids are a diverse group of compounds, for example triacylglycerides, cholesterol, 
phospholipids, vitamins A,D,E,K and many other molecules (3), which are essential 
for diverse biological functions, such as maintaining cell membrane structure and 
function, oxidative metabolism via ß-oxidation, cell signalling, hormone synthesis and 
many others. To serve all these purposes, lipids need to be transported to those  
tissues and cells which require exogenous lipids. As the bloodsystem of all animals is 
aqueous, plasma lipids are transported in form of water-soluble lipoproteins (Fig 
1.1.1). Lipoproteins are spherical complex macromolecules which consist of an  
hydrophobic inner core, made up of cholesteryl-esters (CE) and triacylglycerides and 
a hydrophilic outer surface layer composed of phospholipids, unesterified cholesterol 
and apoproteins (3).  
 
 
 
 
 
 
 
 
 
  
 
                   Fig.1.1.1 Lipoprotein Structure. 
                  (www.nature.com/nrd/journal/v7/n1/images/nrd2353-f1.jpg) 
 
Processing of lipoproteins in the body is called lipoprotein metabolism (Fig 1.1.2), 
and can be divided into two distinct pathways. 
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1. The exogenous pathway, in which dietary lipids and those secreted into the  
intestinal lumen via bile, are taken up by epithelial cells of the small intestine 
and then get secreted in form of chylomicrons into lymph and finally enter the 
bloodstream via the thoracic duct. Lipoprotein lipase (LPL) catalyzes the  
hydrolysis of triacylglycerol, releasing glycerol and free fatty acids (FFA), 
which then can be absorbed by peripheral tissues. Hydrolyzed chylomicrons 
(CM) are called chylomicron remnants and are rapidly taken up by the liver(3). 
2. The endogenous pathway, in which lipoproteins are synthesized by the liver. 
 Lipids are secreted into blood by the liver in form of very low-density 
 lipoproteins  (VLDL),  which circulate through the body and thereby get 
 hydrolyzed by LPL, again resulting in glycerol and FFAs being absorbed by 
 peripheral tissues. Thereby VLDL particles develop into intermediate-density 
 lipoproteins (IDL) which can be taken up by the liver or be further hydrolyzed 
 by hepatic lipase, leading to absorbtion of glycerol and FFAs by the liver. So 
called low-density lipoproteins (LDL), the cholesterol-rich remnants of VLDL,  
are taken up either by peripheral tissues or the liver. Another class of lipopro-
teins, high-density lipoprotein (HDL), mediates reverse cholesterol transport 
from peripheral tissues to the liver, where cholesterol either is converted into 
bile or repackaged into VLDL particles. (3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                         Fig 1.1.2 Lipoprotein metabolism 
                        (www.univie.ac.at/Medbch/MolMed1/Hermannklein08.pdf) 
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1.2 Lipoproteins 
 
Distinct subtypes of lipoproteins differ in size, lipid-, apoprotein composition, and 
density. The latter characteristic is the major basis for classification of lipoproteins. 
Each class of lipoproteins has a specific role in lipoprotein metabolism as already 
described in the chapter above (3).  
 
Name Density 
[g/ml] 
Diameter 
[nm] 
Major Apo-
protein 
Major Lipid 
Component[%] 
Sources 
CM <0.95 100-1000 ApoB48/ 
ApoE 
Triacylglyceride 
84 
Intestine 
VLDL 0.95-1.006 30-80 ApoB100/ 
ApoE 
Triacylglyceride 
50 
Liver 
IDL 1.006-1.019 25-50 ApoB100/ 
ApoE 
Triacylglyceride 
31 
Hydrolyzation 
of VLDL 
LDL 1.019-1.063 18-28 ApoB100 Cholesterol 
50 
Hydrolyzation 
of IDL 
HDL >1.063 5-15 ApoAI/II Cholesterol  
30 
Liver, Intes-
tines 
Table 1.2 Classification of lipoproteins 
 
1.3 Apolipoproteins 
 
Apolipoproteins, also called apoproteins, are the protein components of lipoproteins 
and play key roles in lipoprotein metabolism: 
1. Stabilization of lipoproteins 
2. Together with phospholipids, generation of a hydrophilic surface 
3. Essential for synthesis and secretion of lipoproteins 
4. Transportation of lipids 
5. Binding to specific cell-surface receptors 
6. Decisive for lipid transfer from lipoproteins to cells or vice versa. 
7. Cofactors for specific enzymes, like Lecithin-Cholesterol Acyltransferase 
(LCAT)   
Introduction 
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Apoproteins can be divided into classes and subtypes (Table 1.3).  
 
The most important are:  
1. Apoproteins A (Subtypes: apoA-I, apoA-II, apoA-IV): first found in HDL 
2. Apoproteins B (Subtypes: apoB-48, apoB-100): first found in LDL 
3. Apoproteins C(Subtypes: apoC-I, apoC-II, apoC-III) : first found in VLDL 
4. Apoprotein E(three common isoforms exist : E-1,E-2,E-3, which differ in the 
amino acids at position 112 and 158, and in their functionality) 
Each apoprotein has a specific function and is part of specific lipoproteins. Nonethe-
less, apoproteins can be and in fact are often exchanged between  lipoprotein parti-
cles of different classes, like the transfer of apoC and apoE from HDL to CMs for ex-
ample. 
 Table 1.3 Apoproteins 
 
 
Name Molecular 
Weight [kDa] 
Lipoproteins Function 
ApoA-I 28.5 CM,HDL Activation of LCAT, Binding 
of SRBI (HDL receptor), selec-
tive lipid uptake, reverse cho-
lesterol transport 
ApoA-II 17 CM,HDL Activation of hepatic Lipase 
ApoA-IV 46 CM,HDL Activation of LCAT 
ApoB-48 265 CM Structural element 
ApoB-100 550 VLDL,IDL,LDL Binding to LDL receptor, en-
docytosis 
ApoC-I 6.5 CM,VLDL,IDL Activator of LCAT 
ApoC-II 8.8 CM,VLDL,IDL Activation of LPL 
ApoC-III 8.9 CM,VLDL,IDL Inhibition of LPL 
ApoE 34 CM,VLDL,IDL,HDL Binding to apoB/E receptors 
endocytosis, reverse choles-
terol transport 
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1.4 Cholesterol Metabolism 
 
Cholesterol is  a polycyclic alcohol, that belongs to the lipid class of steroids and is 
essential for many crucial biological functions (3).  
 
 
 
 
 
 
 
 
                       Fig.1.1.4. Structure of Cholesterol  
                      (www.Lipid-liga.de/cms/images/stories/cholesterin.jpg) 
  
In addition to the housekeeping functions of cholesterol in all mammalian cells as a 
key contributor to membrane structure and function, it is the precursor for cytochrome 
P450 cholesterol side chain cleavage enzyme-initiated synthesis of steroid  
hormones. Cholesterol can also be converted to bile acids in the liver and to vitamin 
D in the skin and kidney (3). Therefore, multiple pathways have evolved to ensure full 
supply of animal cells with cholesterol, especially in steroidogenic tissues and the 
liver (3):  
1. Endogenous synthesis from acetyl coenzyme A (acetyl CoA) 
2. Hydrolysis of cholesteryl esters stored in cytoplasmic lipid droplets 
3. Exogenous cholesterol transported to the cells by lipoproteins and taken up 
via cell surface receptor binding, followed by either endocytosis of the  
lipoprotein particle or selective lipid uptake without endocytosis (This will be 
the topic of later chapters of this introduction). 
The homeostasis of cholesterol synthesized endogenously and taken up from the 
diet is regulated by several mechanisms, especially via regulation of 3-hydroxy-3-
methylglutaryl-coenzyme-A-reductase, which catalyzes the rate-limiting step in cho-
lesterol synthesis, the reduction of 3-hydroxy-3-methylglutaryl-coenzym-A to mevalo-
nate. Homeostasis of cholesterol is crucial, as it is essential for living, but on the 
Introduction 
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other hand, high plasma levels of cholesterol (LDL-cholesterol) correlate with athero-
sclerosis and coronary artery disease. Therefore cholesterol metabolism, as well as 
its regulation is a highly interesting research topic and its participating molecules are 
promising targets for novel therapeutic approaches (3).  
 
1.5 Cell Surface Receptors 
 
As already described in the chapter above, 2 different pathways exist for cellular  
uptake of cholesterol from lipoproteins (3).  
1. Endocytotic uptake of LDL particles, mediated by the LDL receptor (LDLR) or 
LDLR relatives (LR), proteins with a high degree of structural similarity to 
LDLR (6).  These receptors form the so-called LDLR supergene family 
2. Selective lipid uptake from HDL, mediated by scavenger receptors class B 
type I and type II (SRBI and SRBII), a process which does not involve  
endocytosis of the lipoprotein particle. 
 
1.5.1 The LDLR  Supergene Family 
 
LDLR (see Fig 1.5.1) is built up of 7 head-to-tail arranged type A binding repeats (LA 
repeats) of ~40 residues, harboring six paired cysteines in identical positions; 3 type 
B repeats also containing six cysteines each, modules of ~50 residues with a  
consensus tetrapeptide, Tyr-Trp-Thr-Asp (YWTD); six of these modules form a so- 
called beta propeller, which together with the type B repeats constitutes the  
epidermal growth factor precursor (EGFP) homology domain; a short stretch rich in 
serines and threonines carrying O-linked sugars (the so called O-linked sugar do-
main); a single transmembrane domain of approximately 20 amino acids; and the  
C-terminal cytoplasmic region with a short signal for receptor internalization (NPxY) 
(6). 
 
 
 
                                                                      Fig.1.5.1 Structure of LDLR 
                                                                      www.univie.ac.at/Medbch/MolMed1/ 
                                                                      Schneider2008.pdf 
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Other proteins of the LDLR supergene family  (Fig 1.5.2) are of the same modular 
basis, but differ in size, number or arrangement of modules and additional domains. 
Prominent members are LDL receptor related protein (LRP1), LRP2, VLDL receptor 
(VLDLR), LDLR relative 11 (LR11/sorLA), ApoE receptor type 2 (ApoER2),  LR7/8B, 
LRP 3,4,5,6 and LRP1B (6).  
 
 
  
    
 
    
 
 
 
 
 
       
    Fig 1.5.2 The LDLR supergene family 
    (www.molecularneurodegeneration.com/content/figures/1750-1326-1-8-2l.jpg) 
 
LDLR is found in most cell types and assembles as cell surface receptor in clathrin-
coated pits of the plasma membrane of animal cells. LDLR binds to  
apoB-100 in LDL particles or to apoE in VLDL and chylomicron remnants, and 
thereby mediates internalization of the bound particles via clathrin-coated vesicles 
and subsequently, endosomes. LDLRs are recycled back to the plasma membrane, 
whereas the endosomes fuse with  lysosomes, where the LDL particle gets  
degraded. Cholesterin can then be further utilized or esterified and stored in a  
cholesteryl ester lipid droplet (3).  
 
1.5.2 Scavenger Receptors 
 
Scavenger receptors are defined as cell surface membrane proteins that bind  
chemically modified lipoproteins such as acetylated LDL, oxidized LDL, and many 
Introduction 
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other types of ligands (1) like sulfated polysaccharides or polynucleotides. Because 
of their broad binding specificity, these receptors have been named scavenger  
receptors. Since the first scavenger receptor has been identified in 1994 by M. 
Krieger and J. Herz, cDNAs of many distinct scavenger receptors have been cloned 
and analyzed, from organisms as diverse as mammals, avians, fish, or fruit flys. 
These receptors have been categorized into broad classes (A,B,C,…) based on 
global structure similarities. In many cases, the members of a given class have been 
subdivided into “types” based on more subtle structural differences, including multiple 
proteins from a single gene generated by alternative RNA splicing (1). In my work I 
focused on scavenger receptor class B type I (SRBI) and its isoform SRBII.  
 
1.6 Scavenger Receptor Class B Type I 
 
SRBI was first identified in 1994 by Endemann, Acton, Krieger and colleagues  in a 
scavenger receptor expression study that used acetylated LDL as ligand. Like other 
scavenger receptors, besides acetylated LDL, SRBI binds a broad class of ligands, 
like oxidized LDL, maleylated BSA, anionic phospholipids, apoptotic cells, unmodified 
LDL and VLDL and, with high affinity, HDL. SRBI therefore was the first identified 
HDL receptor of physiological relevance (1).  
 
1.6.1 Structure of SRBI 
 
SRBI is a member of a family of structurally related proteins, called the CD36  
superfamily, which also includes the mammalian proteins CD36 and LIMPII, D. 
melanogaster proteins emp and croquemort, SnmP-1 and others (3).  
Human SRBI is a protein of 509 amino aicd length, with a horseshoe like topology, 
consisting of a large extracellular loop (403 amino acids) anchored to the plasma 
membrane by N- and C-terminal transmembrane domains (28- and 25 amino acids), 
which have short extensions into the cytoplasma (8 N-terminal- and 45 C-terminal 
amino acids) (1). 8 cysteines are found within the protein, 6 of them are located in the 
loop region, one in the C-terminal transmembrane- and one in the C-terminal  
cytoplasmic domain. The transmembrane (position 426) and cytoplasmic (position 
470) cysteins are palmitoylated (1). SRBI is heavily N-glycosylated, and therefore its 
molecular weight predicted from its amino acid sequence of ~57kDa differs clearly 
                                                                                                                   Introduction                                                                                                                  
 
                                                                                                                                   9 
 
from the observed ~82kDa using immunological methods. In cultered cells, SRBI, just 
like its isoform SRBII, clusters in caveolae-like lipid domains, which are  
clathrin-independent small invaginations of the plasma membrane rich in protein and  
cholesterol. The mechanism by which the subcellular localization of SRBI is regu-
lated is not yet known (1).  
                                               
 
 
 
 
 
 
 
 
 
                                                
                                             Fig.1.6.1 Structure of human SRBI 
          www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid 
                                                          =11560945 
 
1.6.2 Function of SRBI 
 
SRBI facilitates lipid transfer, mainly in form of cholesteryl esters, but also of others 
like phospholipids or α-tocopherol, between different cell types of animals and  
lipoproteins. The main function of SRBI is binding HDL and thereby mediating  
transfer of cholesteryl esters in both directions, either from the hydrophic core of the 
HDL particle into the cell, or the reverse way from the cell to HDL. This mechanism 
neither involves internalization nor lysosomal degradation of the lipopoprotein particle 
and is essential for providing adequate amounts of cholesterol to extrahepatic cells, 
especially those of steroidogenic tissues and for secretion of plasma cholesterol via 
the bile (1,3). 
Introduction 
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Hepatic overexpression of SRBI in mice leads to a decrease in plasma HDL choles-
terol- and apoA-I concentration, as well as to an increase in hepatic bile cholesterol 
concentration (1,3). 
Compared to wild type mice, SRBI knock-out mice , show a 2-2.5 times elevated total 
plasma cholesterol concentration caused by an increase in large HDL particles  
heterozygous in size, which are abnormally enriched in apoE. Plasma apoA-I  
concentration does not change, indicating that impaired selective lipid uptake from 
HDL-CEs is the reason for the increase in total plasma cholesterol levels. The SRBI 
knock-out also decreases biliary- and gallbladder bile cholesterol content, without 
altering bile acid or phospholipid secretion, bile acid poolsize and fecal bile excretion. 
These findings indicate that SRBI is essential for selective lipid uptake and reverse 
cholesterol transport. Therefore, SRBI plays a key role in controlling the structure and 
amount of plasma HDL cholesterol, steroidogenic and hepatic uptake of HDL  
cholesterol, and the use of HDL cholesterol for biliary cholesterol secretion (1,3). 
Net flux of lipids is likely driven by the concentration gradient between cells and  
extracellular donor/acceptor particles (3). Hence enzymatic and non- enzymatic 
modulation of HDL lipid composition may influence net flux of lipids mediated by 
SRBI (3).  
   
Selective Lipid Uptake 
 
Cellular uptake of HDL-cholesteryl esters mediated by SRBI is called selective lipid 
uptake. This process appears to be a two-step process, consisting of (1,3): 
1. High-affinity lipoprotein binding to the receptor 
2. Receptor mediated transfer of cholesteryl esters 
Selective lipid uptake mediated by SRBI is followed by dissociation of the lipid  
depleted lipoprotein from the receptor (1,3).  
SRBI also binds and facilitates selective lipid uptake from LDL and VLDL particles, 
but significantly less efficient than compared with HDL-SRBI interaction. HDL  
competes effectively for LDL binding to SRBI, whereas LDL can only partially  
compete for HDL binding to SRBI (1), a mechanism called nonreciprocal  
cross-competition (NRCC). This indicates that SRBI probably has multiple binding 
sites for different ligands, with different ligand binding properties. The molecular basis 
for this mechanism is not yet understood (1,3).  
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High affinity binding of HDL is mediated by SRBI as well as by  CD36 (its homolog), 
but in contrast to SRBI, CD36 is not able to facilitate selective lipid uptake. Analysis 
of SRBI/CD36 chimeras established that sequences in the extracellular domain of 
SRBI are sufficient to confer efficient selective lipid uptake activity on the cytoplasmic 
and transmembrane domains of CD36, indicating that the extracellular loop of SRBI 
is essential for lipid transfer (3). On the other hand, the carboxy-terminal domain of 
SRBI can influence efficiency of selective lipid uptake, as SRBII facilitates this  
process significantly less efficient, than its isoform SRBI (2,3). Furthermore SRBI 
ligand binding and selective lipid uptake depend on the apolipoproteins present in the 
lipoprotein particle. In case of HDL, apoA-I and apoA-II are the major apoprotein 
components. ApoA-I deficient HDL binds SRBI with high affinity, but no lipid transfer 
occurs (3). ApoA-I and apoA-II composition of HDL particles also seem to influence 
the interaction between the lipoprotein and its receptor. ApoA-II enrichment of HDL 
results in an increased binding affinity for SRBI, but inhibits selective lipid uptake. 
Reconstituted apoA-I/apoA-II-containing particles compared to single apoA-I  
containing particles show decreased binding (3). As experiments with reconstituted 
discoidal apoA-I complexes have shown, either the amino- or the carboxy-terminal 
amphiphatic helices of apoA-I are necessary for binding of these complexes.  These 
findings suggest that the conformation/organization of apoA-I in HDL particles  
critically affects the nature of the interaction of the particle with SRBI (3).  
As already mentioned above, SRBI clusters in caveolae-like, lipid-rich domains of the 
plasma membrane in cultered cells, indicating that these domains might have a  
significant effect on SRBI-mediated lipid transfer (1,3). This hypothesis was sup-
ported by the finding, that in certain cells selective lipid uptake seems to correlate 
with caveolin-1 expression (3). Caveolin-1 is the major contributor to the caveolae 
scaffold and also has cholesterol binding activity. However, it was shown that  
caveolin-1 negatively regulates selective lipid uptake facilitated by SRBI and its  
localization in caveolae-like domains is not necessary for selective lipid uptake. 
These and further findings have shown that SRBI is able to mediate selective lipid 
uptake from SRBI independently from specialized cellular structures or  
compartments (3). 
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Reverse Cholesterol Transport: 
 
Transport of cholesterol from extrahepatic tissues to the liver, where cholesterol is 
either secreted into bile or repackaged into VLDL particles, mediated by SRBI in  
concert with other proteins is called reverse cholesterol transport. The first two find-
ings indicating that SRBI might be involved in reverse cholesterol transport  
were (3): 
1. Caveolae are proposed to be the major sites of cholesterol efflux from cells to 
lipoprotein particles 
2. In different cell lines, expression levels of SRBI correlate with cholesterol ef-
flux to HDL particles 
These findings were supported by the phenotype found in SRBI-KO mice and cell 
culture experiments in which SRBI was blocked either by mutation or with antibodies. 
Reconstitution of HDL particles with mutant apoA-I forms resulted in decreased  
cholesterol efflux to these particles. Formation of a productive complex between 
SRBI and HDL seems to be required for efficient cholesterol transport activity (3).  
 
1.6.3 Regulation of SRBI Gene Expression 
 
To date only little is known about regulation of SRBI expression. The transcription 
factors steroidogenic factor 1 (SF-1), CCAAT/enhancer-binding protein (C/EBP), 
SREBP-1, liver X receptor (LXR) and liver receptor homolog 1 (LRH-1) are supposed 
to play a role in regulation of SRBI gene expression, as consensus-DNA sequences 
were found within the promotor of the human SRBI  gene, which can be bound by 
these transcription factors and by others yet to be identified. These transcription  
factors can be stimulated or inhibited by tropic hormones, cholesterol and polyunsat-
turated fatty acids and other substances (1,3).  
SRBI expression is coordinately regulated with cholesterol metabolism (1). In  
steroidogenic cells, SRBI expression is stimulated by systemic administration of the 
tropic hormone adrenocorticotropic hormone (ACTH) via the cAMP/protein kinase A 
signal transduction pathway, and inhibited by dexamethasone. In testis, SRBI  
expression is stimulated by human chorionic gonadotropin (3).  
High dose estrogen treatment can, in a species-dependent way, either stimulate or 
inhibit SRBI expression in hepatocytes, steroidogenic cells, and macrophages. The 
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SRBI expression of these cells can also be altered by peroxisome  
proliferator-activated receptor (PPAR) agonists, vitamin E, polyunsatturated fatty  
acids, cholesterol, and other agents (1).  
Intestinal SRBI expression is regulated coordinately with cholesterol absorption. 
Taking these findings together it appears that SRBI expression is regulated in a spe-
cies- and cell type-specific way. Thus, versatile regulation systems have evolved. 
 
1.6.4 Tissue Distribution 
 
The highest levels of SRBI expression are found in the liver, which is the central  
organ for lipid metabolism and in steroidogenic tissues, where high amounts of cho-
lesterol are needed for conversion into steroid hormones (1,3). These tissues will be 
discussed in more detail in this chapter. 
Further SRBI-expressing tissues are the intestine, mammary gland of pregnant rats, 
trophoblast, yolk sack and placenta, lung, macrophages, endothelial cells, neuroglia, 
smooth muscle cells, retinal pigmental epithelial cells, and keratinocytes (1,3). 
 
Liver: 
  
The highest total amount of SRBI protein is found in the liver, where 90% of the 
SRBI-mediated selective lipid uptake of cholesteryl esters from HDL occurs. In 
rodents lacking cholesterylester transfer protein (CETP), like rats and mice, 50% of 
total HDL-CE clearance is mediated by the liver, whereas in CETP-expressing 
animals it is only about 20%. HDL-cholesterol taken up by the liver is either 
converted into bile or repackaged into VLDL particles (3). 
Under basal conditions, hepatic SRBI is mostly expressed on the sinusoidal surface 
of parenchymal cells. Further hepatic SRBI expression has been reported in liver 
endothelial cells and Kupffer cells (3). Estrogen treatment of rats resulted in a shift of 
total liver protein expression from SRBI to SRBII (see point 1.7) and to decreased 
SRBI expression in parenchymal cells, in contrast to an increase in SRBI expression 
in Kupffer cells. Chronic ACTH stimulation in rats and mice resulted in a decreased 
hepatic SRBI expression. It was found that the adrenals, under such circumstances, 
release a factor repressing hepatic SRBI expression and thereby ensure that enough 
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lipoprotein cholesterol is available (3). These findings strongly suggest that hepatic 
SRBI expression is sensitive to hormonal regulation. Dietary cholesterol changed 
SRBI expression patterns in parenchymal and Kupffer cells of rat liver analog to 
estrogen treatment. No differential expression of liver SRBI, induced by dietary 
cholesterol, was found in hamsters or mice (3). Thus, hepatic regulation of SRBI by 
dietary cholesterol seems to be species-dependent. Further substances influencing 
SRBI expression, reported at least for chinese hamster, are plant-derived 
polyunsatturated fatty acids, dietary myristic acid, α-tocopherol, LPS, TNF, IL-1, and 
insulin (3).  
 
Adrenal Gland: 
 
The highest expression levels of SRBI per gram of tissue have been found in rodent 
adrenal glands (3). The adrenal gland needs high amounts of cholesterol as 
substrate for synthesis of mineralocorticoids, glucocorticoids, androgens, and small 
amounts of estrogens, thereby explaining the high concentration of SRBI protein per 
gram tissue. SRBI is found primarily on the surfaces of steroidogenic parenchymal 
cells, where it is essential for ACTH-induced microvilli-rich adrenal channel formation 
(3). These channels are generated by intercellular dimerization of SRBI and serve 
the purpose of trapping lipoprotein particles. Thus, they are the major site of selective 
lipid uptake. ACTH induces this process by stimulating SRBI expression, reported for 
mouse adrenocortical cells in vivio, as well as for cultured human adrenocortical 
cells. Dexamethasone has a contrary effect and inhibis SRBI expression in 
adrenocortical cells (3). Estrogen treatment of rats leads to an increase in 
adrenocortical SRBI expression, followed by enhanced binding of HDL to the 
adrenocortical cell surface and increased selective uptake of cholesteryl esters from 
HDL. ACTH seems to be a crucial factor in this process, as hypophysectomy 
dramatically decreases adrenal SRBI expression, and chronic estrogen therapy 
affects ACTH secretion (3). 
 
Ovaries: 
 
In the ovaries, SRBI expression patterns depend on the stage of the estrus cycle. 
During the preovulatory stage, SRBI expression is found only in theca interna cells. 
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These cells convert cholesterol into androgens and therefore need adequate choles-
terol supply (3). In granulosa cells, which convert androgens into estrogens, no SRBI 
expression occurs. During luteinization, initiated by luteinizing hormone (LH), SRBI 
expression shifts from theca interna cells to granulosa cells, which then develop into 
the corpus luteum, synthesizing progesterone and small amounts of estrogen (3). 
Consistent with that, estrogen administration to rats results in increased SRBI ex-
pression, selective lipid uptake, and steroidogenesis in the ovaries. Also, high-dose 
treatment of rats with estrogen, which resembles the situation before ovulation, shifts 
SRBI expression from theca interna cells to granulosa cells (3). 
 
Testis: 
 
In Leydig cells, which synthesize androgens, like testosterone essential for sper-
matogenesis, most of testicular SRBI expression is found, whereas in Sertoli cells, 
which nurture the developing sperm cells, but also have some other functions like 
synthesis of the anti-Müllerian hormone during embryogenesis, little SRBI expression 
occurs (3). Levels of SRBI are very low in general, correlating with very low selective 
lipid uptake from HDL particles, indicating indepence of Leydig cells from exogenous 
cholesterol sources for steroidogenesis. Consistent with that, no defects in fertility 
have been detected in male SRBI knockout mice. Yet, gonadotropin increases SRBI 
expression in Leydig cells, resulting in an increase in SRBI-mediated selective up-
take of cholesteryl esters from HDL particles, followed by an increase in steroid hor-
mone synthesis. Thus, it seems like Leydig cells are not dependent on HDL-derived 
cholesterol, but nonetheless can use it as source (3). 
 
1.6.5 Physiological Role of SRBI 
 
As SRBI is expressed in many and diverse types of tissues and cells, and contributes 
to many crucial biological functions as mentioned above, it is not surprising that SRBI 
has been reported to be involved in diverse physiological and pathophysiological 
processes like atherosclerosis, female fertility, cholesterol gallstone disease, intesti-
nal cholesterol absorption, embryogenisis and fetal development, red blood cell 
maturation, nitric oxid metabolism, and vitamin E transport (3). Atherosclerosis might 
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be the most relevant pathophysiological process in which SRBI is crucial, and there-
fore is also the most investigated one. Hence in this chapter I will focus on athero-
sclerosis, but also on female fertility, as in 10-20% of human infertile females the 
cause is unknown and abnormal lipoprotein metabolism due to mutations in SRBI 
might be the underlying problem (3,4). 
 
Atherosclerosis: 
 
Atherosclerosis is a systemic disease of the arteries due to a chronic inflammatory 
response in the vessel walls. This inflammation process is initiated by invasion of the 
endothelium by oxidized LDL, thereby damaging the arterial wall.  In response to this 
damage, macrophages accumulate and absorb oxidized LDL particles. These 
macrophages then develop into so-called foam cells, which attract further  
macrophages, thus prolongating the inflammatory response, resulting in tissue  
remodelling, atherosclerotic plaque formation and blood clotting that narrows the 
blood vessels (3). This is a process that takes decades, but finally can lead to  
ischemia, thrombosis, embolism, coronary artery disease, and appoplexy.  
Coronary artery disease is the major cause of death in western industrialized  
countries and it is long known that low plasma HDL levels and coronary artery  
disease are associated. The mechanism by which HDL mediates its cardioprotective 
effect is not yet known, but it is most probably due to reverse cholesterol transport 
(3). Therefore, SRBI might influence atherosclerosis and all associated diseases  by 
mediating uptake of cholesteryl esters from peripheral tissues by HDL, transport and 
transfer of this CEs to the liver, and secretion into bile. Some experiments were  
performed to gain insight into the role of SRBI in prevention or development of 
atherosclerosis. Different mouse models have been used which had a genetic  
background that made them susceptible to atherosclerosis. The following mouse 
models exhibit increased levels of apoB-containing particles with atherogenic  
properties and therefore have increased levels of plasma total cholesterol (3): 
1. The LDLR knock out mouse 
2. The human apoB transgenic mouse fed a high fat/high cholesterol (West-
ern type) diet  
3. The apoE knock out mouse 
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ApoE/SRBI double-knock out mice fed a normal chow diet, compared to apoE 
single knock out mice show a dramatic acceleration of atherosclerosis, especially 
in the aortic sinus and coronary arteries, already at week 4-7 after birth. This 
model is quite a good one for human atherosclerosis, as the coronary arterial le-
sions of these mice resemble remarkably those in human patients (3).  
The cardioprotective effect of SRBI was shown by an experiment using LDLR 
knock out mice. Transient hepatic overexpression of SRBI, using an adenoviral 
system, in these mice fed a Western type diet, decreased plasma HDL cholesterol 
significantly. Surprisingly, even though non-HDL particles were not affected, areas 
of atherosclerotic lesions were reduced relative to untreated LDLR knock out  
control mice. Lesion size of individual mice correlated with their mean  
HDL-cholesterol level, but in some cases also with their mean non-HDL  
cholesterol level. The anti-atherosclerotic effect mediated by SRBI thus seems to 
be based on changes in net cholesterol flux, or maybe also by reduction of  
non-HDL cholesterol levels (3).  
In another experiment, human apoB transgenic mice were used to study the  
effects of varying levels of stable SRBI expression in the liver. Both low and high 
levels of SRBI expression were failed to produce any protective effect. Only  
moderate levels of SRBI expression in the liver showed anti-atherogenic effects 
(3). Therefore, the role of SRBI in atherogenesis is very complex and may depend 
not only on the levels of SRBI expression, but also  on the atherogenesis model 
used.  
 
Female Fertility: 
 
Female, but not male, SRBI-KO mice are infertile, even though they exhibit normal 
estrus cycle, ovulation, and progesterone levels during pseudopregnancy. This  
infertility is due, at least in part, to the ovulation of dysfunctional oocytes (4). 
Transplantation of ovaries from SRBI knock out mice into ovariectomized  
SRBI-positive mice rescued the ovarian wild type phenotype, and 6 out of 7 mice 
became pregnant. The litters were all heterozygous for the SRBI mutation, proving 
that the oocytes from which these mice developed, originated from the  
SRBI-negative ovaries transplanted into the SRBI positive mice. Thus, ovarian 
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SRBI expression doesn´t seem to be essential for embryonic development, adult 
maturation or ovarian function, if an extraovarian environment is provided which 
exhibits SRBI expression. In addition, treatment of SRBI knockout mice with  
probucol, which lowers HDL-cholesterol levels, restored fertility (4).  
Based on these experiments, it seems as if abnormal lipoprotein metabolism in 
SRBI knock out mice is responsible for female infertility. As already mentioned 
above, absence of SRBI in mice results in large and heterogeneously-sized HDL 
particles  abnormally enriched in apoE, and plasma total cholesterol levels are 
elevated 2-2.5 times. So, maybe these HDL particles are not able to transport  
important fertility factors to the oocytes, or these abnormal lipoproteins actively 
somehow inhibit critical ovarian functions (1,3,4).  
In any case, additional investigations of potential relationships between abnormal 
lipoprotein metabolism and human female infertility of unknown etiology may be 
informative and may possibly lead to new therapeutic approaches (4). 
 
1.7 Scavenger Receptor Class B Type II 
 
SRBI and SRBII are alternatively spliced products from a single gene (Fig. 1.7) 
and differ only in their carboxy-terminal cytoplasmic domain. Exon 12 of SRBI, a 
129 nt long sequence of the SRB gene transcript, is removed and thereby the stop 
codon of SRBI is lost. A 3´-untranslated region of SRBI then gets attached to exon 
11 and thereby becomes a coding exon (exon 13), with another stop codon at its 
3´end. This transcript then becomes translated into the protein SRBII (2).  
Human SRBI, as mentioned above, is 509 amino acids long, and the last 47 
amino acids, all of them part of the cytoplasmic domain of SRBI, get replaced by 
44 amino acids of the alternative exon 13 of SRBII (2). 
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                                Fig.1.7 Alternative Splicing of SRBI and SRBII 
                                www.jbc.org./cgi/content/full/273/24/15241/F1 
 
 
The isoform SRBII has been found in many organisms, like human, cattle, rat, and 
mouse. The open reading frame coding for SRBII in these organisms is of the same 
length, encoding 506 amino acids; furthermore, the nucleotide sequences in this 
SRBII-specific exon are highly conserved (2).  
Just like SRBI, SRBII is found in the plasma membrane and clusters in caveolae-like 
cholesterol-rich domains. SRBII also gets extensively N-glycosylated and  
palmytoylated, and both isoforms have similar binding affinities for HDL and mediate 
selective lipid uptake, but the efficieny of SRBII in mediating both cholesterol influx 
from HDL to cells and cholesterol efflux from cells to HDL is approximately 4 times 
lower than that of SRBI (2). 
SRBII protein accounts for 5-12% of total SRB protein in mouse liver, testis and  
adrenal glands, but 30-80% of total SRB mRNA. Half-lifes of the mRNAs of the two 
isoforms are similar. Thus, the difference in protein levels might be resulting from  
different translation efficiencies of SRBI and SRBII mRNAs. Anyhow, little is known 
about splice site selection and mRNA:protein ratio differences, but  estrogen seems 
to play a key role (2).  
Estrogen-treatment of rats, especially in the more potent synthetic form of  
17-α-ethynyl estradiol, can influence SRBI and SRBII levels in a dose- and  
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glycosylation- state dependent manner, in the liver. Both glycosylated and  
nonglycosylated SRBI levels decrease, non-glycosylated SRBII increases and  
glycosylated SRBII doesn´t seem to be influenced. Glycosylation is proposed to play 
a role in the folding and export of the SRBI protein from the endoplasmatic reticulum, 
and it is not yet known wether or not glycosylation of SRBII is important for its  
stability, subcellular localization or lipid transfer activities, but it appears that post-
translational modification of SRBII may be one of the factors in estrogen’s effect on 
rat liver cells (5).   
Splicing factors involved in alternative splicing of SRB are ASF/SF2, Tra-2α and 
Tra-2β. Overexpression of these splicing factors in rat liver results, in the case of 
ASF/SF2, in upregulation of SRBI expression and downregulation of SRBII  
expression, but in the case of Tra-2α and Tra-2β in a downregulation of SRBI ex-
pression and upregulation of SRBII expression. 17-α-ethynyl estradiol treatment of 
rats  
induced an increase in Tra-2β expression in the liver, but did not influence ASF/SF2 
levels of expression. The result is obtained when HepG2 cells are stimulated with  
17-α-ethynyl estradiol. Therefore it seems that estrogen affects SRB splicing at least 
partly through the regulation of Tra-2β (5).  
The findings listed above suggest that estrogen is able to influence alternative 
 splicing of SRB mRNA and post-translational modification of SRB proteins. 
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2 Materials and Methods 
 
2.1 Animals 
 
Derco brown laying hens (30-40 weeks old) were purchased from Heindl Co.  
(Vienna, Austria) and maintained on layer’s mash with free access to water and feed 
under a daily light period of 16 hours. 
 
2.2 Molecular Biology: 
 
2.2.1 Bacterial Strains and Vector Systems 
 
Strain  
 
 
One Shot TOP10 Chemically 
Competent E.coli 
 
One Shot BL21 Competent 
Cells 
 Genotype F−mcrA ∆(mrr-hsdRMS-
mcrBC)  Φ80lacZ∆M15 
∆lacX74 recA1 araD139 
∆(araleu)7697galU galK rpsL 
(StrR)endA1 nupG 
 
F- ompT  hsdSB  (rB-mB-) gal  
dcm  (DE3) 
 
Reference/Source Invitrogen Invitrogen 
Table 2.2.1 Bacterial strains used for transformation 
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Vector 
 
PET-25b(+) pCR2.1-TOPO 
 
 
Size 
 
5547 basepairs 3931 basepairs 
 
Genotype characteristics 
 
T7 promotor, T7 tran-
scription start, pelB cod-
ing sequence, multiple 
cloning sites, HSV tag, 
His tag, T7 terminator, 
lacI coding sequence, 
pBR322 origin, bla cod-
ing sequence, f1 origin 
LacZ α gene, M13 reverse 
priming site, MCS, T7 pro-
moter/priming site, M13 for-
ward priming site, f1 origin, 
kanamycin resistance, ampicil-
lin resistance, pUC origin 
 
Reference/Source 
 
Novagen Invitrogen 
 
Table 2.2.2 Vector systems used for cloning 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.1 Genetic map of pET-25b(+) and pCR2.1-TOPO Vector 
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2.2.2 Oligonucleotide Primers 
 
Name Sequence Tm[°C] %GC 
ggSRB1-FWD1 5´-TGA GGA TTG ACC CCA GCA-´3 56  
ggSRB1-REV1 5´-GCA TCG GGG CTG TAG AAC-´3 58,2  
ggSRBI-Fwd1-
NcoI 
5´-TAC CAT GGA TGT GAG GAT TGA 
CCC CAG C-3´ 
68 53,6 
ggSRBI-Rev1-
EcoRI 
5´-ATG AAT TCT TGG CAT CGG GGC 
TGT AGA AC-3´ 
66,7 48,3 
ggSRBI-Fwd4 5´-CGC CAT CGT CAA GGA GCA-3´ 58,2 61,1 
ggSRBI-Rev4 5´-GGG GTC GTG TGG GTG CTT-3´ 60,5 66,7 
ggSRBI-Rev5 5´-GAC ACG TCC CCT TCT GGA G-3´ 61 63,2 
ggSRB-F1      5´-GCG CTC TGC GAG CCA TGG-3´ 62  
GgSRBII-Fwd1 5´-GAT GGC TCA GTC CTA TCG-3´ 56 55,6 
GgSRBII-Rev1 5´-CAG AAG TGG GGT GTA G-3´ 52 56,3 
GgSRBII-Rev2 5´-TGT CCG CTG AGA GAC TCC-3´ 58,2 61,1 
GgSRBII-Rev3 5´-CAT CAG GGA CTC AGA GTA GGC-3´ 61,8 57,1 
GgSRBII-Fwd3 5´-TGT TCA TCT CCC ACC CTC AC-3´ 59,4 55 
ggSRBII-Fwd1.2 5´-GAT GGC TCA GTC CTA TCG CAG-3´ 61,8 57,1 
Table 2.3.1 Oligonucleotides used for PCR of laying hen liver tissue cDNA. The de-
signed oligonucleotides were synthesized by MWG-Biotech AG, Ebersberg,  
Germany. 
 
Oligonucleotide primers were designed using a Gallus gallus SRBI sequence derived 
from ENSEMBL (ENSGALG00000003018) and the online programs ClustalW and 
Pearl Primer.   
 
2.2.3 RNA Isolation 
 
Total RNA was isolated using NucleoSpin RNA II kit from Macherey-Nagel or TRI 
Reagent from Molecular Research Center, Inc. 
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2.2.4 RNA Isolation using TRI Reagent from Molecular Research Center, Inc. 
 
200mg of frozen chicken tissue were placed in a 15ml Falcon tube, chilled on ice and 
homogenized in 2ml TRI reagent (1ml per 100mg tissue), using an Ultra-Turrax-T25-
Homogenizer. In between two different tissues the ultra-turrax was cleaned with  
diethyl pyrocarbonate (DEPC) [0,1%] water and 70% ethanol). After homogenization 
the lysates were incubated for 5 minutes (min) at room temperature. 400µl  
chloroform were added and the Falcon tubes were vigorously shaken, followed by 
15min of incubation at room temperature. After incubation, the tubes were  
centrifuged for another 15min at 12000xg and 4°C. T he aquous phase was  
transferred into a new Falcon tube and 1ml isopropanol was added. The tube was 
vigorously shaken and another time incubated for 10min at room temperature. After 
incubation the tubes were centrifuged for  30min at 12000xg and 4°C. The  
supernatant was discarded and the pellet washed in 2ml  pure ethanol. After 5min of 
centrifugation at 12000xg and 4°C ethanol was remov ed and the RNA pellet dryed at 
the air. Finally the RNA pellet was dissolved in 50µl sterile DEPC (0,1%) water, put 
into a sterile Eppendorf tube and incubated at 60°C  for 10min, gently shaking. After 
photometric determination of the RNA concentration the samples were kept at –80°C.  
 
DEPC H2Odd 
2ml diethyl pyrocarbonate [100%] (DEPC) 
double destilled (dd) H2O up to 2000ml 
 
DEPC.H2O was incubated at room temperature overnight and autoclaved the next 
day. DEPC.H2O was stored at room temperature. 
 
Determination of RNA concentration 
For determination of RNA concentration samples were diluted 1:1000 or 1:100  
(depending on the RNA concentration in the samples) with DEPC.ddH2O. Absorb-
ance was measured in quartz cuvettes at a wavelength of 260nm.The RNA concen-
tration was then calculated as following: 
 
Extinction at 260nm × dilution factor (100 or 1000) × 40 = ng / µl RNA 
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2.2.5 RNA Isolation using NucleoSpin™ RNA II kit from Macherey-Nagel 
 
30mg frozen chicken tissue were placed in a sterile glass potter. 350µl buffer RA1 
and 3.5µl ß-mercapthoethanol were added and the tissue was homogenized. The 
lysate was then loaded onto a nucleospin filter unit and centrifuged for 1min at 
11000xg. The filter unit was discarded and 350µl 70% ethanol were added to the  
lysate, which was then shaken vigorously. The lysate was then loaded onto a nucleo 
spin RNA II cloumn and centrifuged for 30seconds (sec) at 8000xg. 350µl membrane 
desalting buffer were added and the column was centrifuged for 1min at 11000xg. 
The flowthrough was discarded and the membrane was incubated for 15min at room 
temperature with 95µl of DNAse reaction mix  (10µl DNAse I and 90µl DNAse  
reaction buffer). After incubation, 200µl buffer RA2 were added and the solution was 
centrifuged for 30sec at 8000xg. Flowthrough was discarded. 650µl buffer RA3 were 
added, followed by another centrifugation step of 30sec at 8000xg. Then, 250µl of 
buffer RA3 were added and the column was centrifuged for 2min at 11000xg, and the 
nucleospin column was placed on a nuclease free collection tube. To elute bound 
RNA, 60µl RNAse free water were added and collected through centrifugation for 
1min at 11000g.   
 
2.2.6 cDNA Synthesis  
 
cDNA synthesis was carried out using SUPERScript RNase H− Reverse  
Transcriptase from Invitrogen. Total RNA was isolated out of 30mg chicken liver  
tissue using a Nucleo Spin RNA II Kit from Macherey-Nagel and the following  
components were mixed in a sterile Eppendorf tube: 
10µl total RNA 
1µl dNTPs (10mM each) 
1µl Oligo (dT) (500µg/ml) 
The mixture was heated to 65°C for 5 minutes and th en chilled on ice. The following 
components were added: 
4µl First Strand Buffer 
2µl 0.1M DTT 
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After an incubation at 42°C for 2min, 1 µl SUPERSCRIPT II reverse transcriptase 
(200 U/µl) was added and mixed by pipetting. The cDNA synthesis reaction was  
performed at 42°C for 50 minutes and finally stoppe d by heating to 70°C for 15 min. 
For elimination of RNA, 2 units of RNase H (Roche) were added and incubated at 
37°C for 20 minutes. cDNA samples were stored at –2 0°C. 
 
2.2.7 Polymerase Chain Reaction (PCR) 
 
Different PCR reaction mixtures and programs were used, depending on the different 
primer sets. 25µl reactions were used. The following components were pipetted on 
ice and gently mixed in a sterile PCR reaction tube: 
 
0.5µl cDNA 
2.5µl 10xPCR Reaction Buffer [15mM MgCl2] 
0.5µl ggSRB1-FWD1 [25pM] 
0.5µl ggSRB1-REV1 [25pM] 
1µl dNTP mix [10mM each dNTP] 
0,5µl Polymerase [1U/µl] 
0/0.5/1/2µl DMSO  
x µl sterile ddH2O to a final volume of 25µl 
 
Finnzymes Dynazyme Taq Polymerase EXT was used for optimization of polymerase 
chain reactions, whereas Fermentas High Fidelity Taq Polymerase was used if the 
PCR product was to be sequenced.  
The following PCR programs were used: 
 
Table 2.2.7.1 PCR program used for 
primer set  ggSRBI- Fwd1/Rev1. 
 
 
 
 
 
Initial Denatura-
tion 
94°C 5´ 1x 
Denaturation 94°C 30´´  
Annealing 56°C 30´´ 30x 
Extension 72°C 1´  
Final Extension 72°C 10´ 1x 
Pause 4°C   
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Table 2.2.7.2 PCR program  used for 
primer set  ggSRBI-f1-NcoI/r1-EcoRI 
 
 
 
 
 
 
Table 2.2.7.3 PCR program  used for 
primer set  ggSRBI-Fwd4/Rev4 
 
 
 
 
 
 
Table 2.2.7.4 PCR program used for 
primer set  ggSRBI-F1/Rev5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial Denatura-
tion 
94°C 5´ 1x 
Denaturation 94°C 30´´  
Annealing 63°C 30´´ 40x 
Extension 72°C 1´  
Final Extension 72°C 10´ 1x 
Pause 4°C   
Initial Denatura-
tion 
94°C 5´ 1x 
Denaturation 94°C 1´  
Annealing 56°C 30´´ 40x 
Extension 72°C 2´  
Final Extension 72°C 10´ 1x 
Pause 4°C   
Initial Denatura-
tion 
94°C 5´ 1x 
Denaturation 94°C 1´  
First Annealing 64°C 30´´ 3x 
Elongation 72°C 2´30´´   
Denaturation 94°C 1´  
Second Anneal-
ing 
61°C 30´´  3x 
Elongation 72°C 2´30´´   
Denaturation 94°C 1´  
Final Annealing 58°C 30´´  34x 
Elongation 72°C 2´30´´   
Final Elongation 72°C 10´ 1x 
Pause 4°C   
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Table 2.2.7.5 PCR program 1 used for 
primer set  ggSRBII-Fwd1/Rev1 
 
 
 
 
 
 
 
 
Table 2.2.7.6 PCR program 2 used for 
primer set  ggSRBII-Fwd1/Rev1 
 
 
 
 
 
 
 
Table 2.2.7.7 PCP program used for 
primer set  ggSRBII- Fwd3/Rev3 
 
 
 
 
 
 
 
 
 
 
 
Initial Denaturation 94°C 5´ 1x          
Denaturation 94°C 30´´  
Annealing 51°C 30´´ 40x 
Extension 72°C 30´´  
Final Extension 72°C 10´ 1x 
Pause 4°C   
Initial Denatura-
tion 
94°C 5´ 1x 
Denaturation 94°C 30´´  
First Annealing 49°C 30´´ 6x 
Elongation 72°C 30´´  
Denaturation 94°C 30´´  
Final Annealing 52°C 30´´  34x 
Elongation 72°C 30´´  
Final Elongation 72°C 10´ 1x 
Pause 4°C   
Initial Denatura-
tion 
94°C 5´ 1x 
Denaturation 94°C 30´´  
First Annealing 52°C 30´´ 3x 
Elongation 72°C 1´  
Denaturation 94°C 30´´  
Second Anneal-
ing 
55°C 30´´  3x 
Elongation 72°C 1´  
Denaturation 94°C 30´´  
Final Annealing 58°C 30´´  34x 
Elongation 72°C 1´  
Final Elongation 72°C 10´ 1x 
Pause 4°C   
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Table 2.2.7.8 PCR program used for 
primer set ggSRBII-Fwd1.2/Rev3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All PCR products were analyzed by agarose gel electrophoresis. 
 
2.2.8  Agarose Gel Electrophoresis 
 
Separation of DNA fragments was performed by gel electrophoresis using 1% (w/v) 
agarose gels with a constant voltage of 130V. DNA samples were mixed with  
5× DNA loading buffer containing Bromophenol Blue or Xylene Cyanol FF serving as 
front marker. 1× TAE was used as electrophoresis running buffer. The 1kb Plus DNA 
Ladder from Invitrogen was used as size marker. To visualize DNA fragments under 
ultraviolet light (366 nm), the agarose gel contained (1:10 000)the fluorescent  
intercalating dye ethidium bromide (40µg/100 ml). 
 
50× TAE, pH 8.0                  Ethidium bromide stock solution                                                                       
2M Tris-HCl                          10mg/ml ethidium bromide in H2Odd.          
1M Acetic acid 
0.1M EDTA 
 
Initial Denatura-
tion 
94°C 5´ 1x 
Denaturation 94°C 1´  
First Annealing 55°C 30´´ 3x 
Elongation 72°C 30´´  
Denaturation 94°C 1´  
Second Anneal-
ing 
58°C 30´´  3x 
Elongation 72°C 30´´  
Denaturation 94°C 1´  
Final Annealing 61°C 30´´  34x 
Elongation 72°C 30´´  
Final Elongation 72°C 10´ 1x 
Pause 4°C   
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5× DNA loading buffer 
5ml 100% Glycerol 
2ml 0.5M EDTA 
12ml 50× TAE 
3ml H2Odd 
Bromophenol blue or Xylene Cyanol FF 
 
2.2.9 DNA Gel extraction 
 
All gel extractions were performed using QIAquick Gel Extraction Kit (QIAGEN). All 
centrifugation steps were carried out in a table-top microcentrifuge. The desired DNA 
band was excised from the agarose gel with a sterile scalpel and transferred to an 
Eppendorf tube. 3 volumes of buffer QG were added to 1 volume of gel (100 mg gel 
weight = 1 volume of gel = 300µl buffer QG). The gel was dissolved completely by 
incubating at 50°C for 10 minutes and repeated vort exing every 2-3 minutes during 
incubation. 100µl Isopropanol were added and the sample was mixed. The solution 
was then loaded onto a QIAquick column and centrifuged for 1min at 14000rpm. The 
flowthrough was discarded, 750µl buffer PE(+EtOH) were added and the column was  
centrifuged again for 1min at 14000rpm. The flowthrough was discarded and to  
completely dry the column, another centrifugation step was done for 1min at 
10000xg. The DNA was then eluted by loading 30µl EB buffer (10mM Tris-HCl pH 
8.5), incubation for 1min at room temperature and centrifugation for 1min at 14000 
rpm.  
 
2.2.10 Cloning 
 
2. 2.10.1 Topo TA Cloning  
 
Taq-polymerase used for PCR has a nontemplate-dependent terminal transferase 
activity that adds a single deoxyadenosin (A) to the 3’ ends of PCR products.   
Linearization of pCR2.1-TOPO vector results in a single overhanging  
3’ deoxythymidine (T) residue. Topoisomerase I, which is covalently bound to this 
vector allows Taq-polymerase derived PCR products to insert into the linearized  
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vector without adding DNA ligase to the reaction. The following components were 
pipetted into Eppendorf reaction tubes:  
 
4µl PCR product (purified by gel extraction) 
1µl salt solution (1.2 M NaCl; 0.06 M MgCl2) 
1µl TOPO vector (pCR2.1-Topo) 
 
This reaction mixture was incubated for 10 minutes at room temperature and then 
used for transformation. 
 
2. 2.10.2 Cloning using  pET-25b(+) as vector 
 
To generate an antibody specific for SRBI and SRBII, pET 25b(+) was chosen as 
vector system for recombinant protein expression. Due to the vector characteristics 
the recombinant protein will be secreted into the periplasma of the transformed  
bacteria and contain a 6xHistidine tag attached to its carboxy-terminal end, which 
should ease purification of the expressed protein. The following components were 
pipetted into Eppendorf reaction tubes. Each enzyme and buffer was derived from 
Roche. 
 
0.5µg pET-25b(+) DNA (Midiprep) 
1µl each NcoI/EcoRI restriction enzyme 
2µl SURE Cut Buffer H 
xµl ultrapure ddH2O to a final volume of 20µl 
 
3µg Insert DNA (Midiprep) 
1µl each NcoI/EcoRI restriction enzyme 
2µl SURE Cut Buffer H 
xµl ultrapure ddH2O to a final volume of 20µl 
 
These mixtures were gently shaken for 24 hours at 37°C. Insert excision and vector 
linearization, caused by the restriction enzyme treatment was then checked using 1% 
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agarose gel electrophoresis. 20µl of the insert restriction enzyme mixture and 1µl of 
the vector restriction enzyme incubation mixture were loaded onto that gel. The  
excised insert of correct length was then extracted using QIAquick Gel Extraction Kit 
and stored at -20°C. The remaining 19µl of vector r estriction enzyme reaction were 
then dephosphorylated. The following components were pipetted into an Eppendorf 
reaction tube.  
 
19µl vector restriction enzyme mixture 
4µl SAP buffer 
3µl SAP (shrimp alkaline phosphatase) 
xµl ulttrapure ddH2O to a final volume of 40µl 
 
This dephosphorylation mixture was then incubated gently shaking for 15min at 
37°C. Afterwards SAP was inactivated by gently shak ing the mixture for 20min, at 
65°C. The vector then was precipitated and therefor e the following components were 
pipetted into an Eppendorf reaction tube: 
 
40µl dephosphorylation mixture 
54µl isopropanol 
28µl 1M autoclaved sodium-acetate 
14µl utrapure ddH2O 
 
The reaction tube was then vortexed and stored at –20°C overnight. The next day it 
was centrifuged for 30min at 13000rpm and 4°C. The supernatant was discarded and 
the pellet was washed with 1ml 70% ethanol, followed by another centrifugation step 
for 10min at 13000rpm and 4°C. Again the supernatan t was discarded and the pellet 
was dried for 10min at 37°C. Now the insert and vec tor DNA could be ligated. Thus 
the following components were pipetted onto the dry vector pellet: 
 
17µl Insert 
2µl 10xligation buffer 
1µl T4 ligase 
This mixture then was placed into a 14°C water bath  and kept there overnight. 10µl of 
this mixture were used for transformation of chemically competent E.coli BL-21. 
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 2.2.11 Transformation of chemically competent E.coli 
 
25µl bacterial solution (kept frozen at –80°C) were  slowly thawed on ice, added to the 
cloning mixture and  mixed gently. The reaction was incubated on ice for 30min. 
Then, the cells were heated for 30sec at 42°C and c hilled on ice for 2 min. For  
regeneration, 200µl of provided S.O.C. medium were added and the cells were  
incubated for 1 hour at 37°C under gentle shaking. 50µl and 150µl of the  
transformation mixture were plated onto LB-Amp/X-Gal plates (50µl of X-Gal 
[50mg/ml] per LB-Amp plates) and incubated overnight at 37°C. 
 
LB-Amp plates 
10g Peptone from Casein 
5g Yeast Extract 
10g NaCl 
12g Agar-Agar 
H2Odd ad 1000ml 
100µg/ml Ampicillin 
 
2.2.12 Preparation of Plasmid DNA 
 
Preparation of plasmid DNA was carried out using FastPlasmid Mini Kit from  
Eppendorf and QIAfilter Plasmid Midi Kit from QIAGEN. DNA concentration was  
determined analogous to RNA concentration determination by UV spectrophotometry 
at 260nm and calculation of the concentration according to the following equation: 
 
Extinction at 260nm × dilution factor × 50 = ng / µl DNA   
 
LB medium                   LB-Amp                   TE buffer                                                         
10g Trypton                   LB medium               10mM Tri-HCL, pH 8       
5g Yeast Extract           100µg/ml Amp           1mM EDTA 
10g NaCl 
H2O dd. ad 1000 ml 
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2. 2.12.1 Miniprep 
 
A single white bacterial colony from an LB-Amp plate was transferred into 5ml of  
LB-Amp medium and incubated at 37°C overnight, shak ing vigorously. 1.5ml of the 
bacterial culture were transferred into an 2ml Eppendorf tube and harvested by  
centrifugation for 1 minute at 12000xg. The supernatant was removed and the pellet 
was resuspended in 400µl of ice-cold complete lysis solution by vortexing at highest 
setting for 30sec. The cell lysate was incubated at room temperature for 3 min,  
transferred to a Spin Column Assembly by pipetting and centrifuged for 1min at 
14000rpm. The flowthrough was discarded and bound DNA was washed by adding 
400µl of Wash buffer and centrifugation for 1min at 14000rpm. To dry the column, the 
flowthrough was again discarded and the column one more time centrifuged for 1min 
at 14000pm. The column was put onto a collection tube and DNA was eluted by  
adding 50µl of EB buffer and a final centrifugation for 1min at max. speed. Plasmid 
DNA samples were stored at –20°C.  
 
2. 2.12.2 Midiprep 
 
A single white bacterial colony from an LB-Amp plate was transferred into 2ml  
LB-amp medium and was incubated for 8 hours, at 37°C, vigorously shaking. Then, 
25ml of LB-amp medium were inoculated with 50µl of that starter culture. This culture 
was then incubated for 16 hours at 37°C, again vigo rously shaking.  Bacterial cells 
were harvested by centrifugation at 6000xg for 15min at 4°C.  Bacterial pellets were 
resuspended in 4ml buffer P1. Another 4ml buffer P2 were added and the solution 
was mixed vigorously by inverting the sealed tube 6 times, followed by another  
incubation step for 15min at room temperature. Subsequently, 4ml of chilled buffer 
P3 wered added to the lysate and again the lysate was mixed by inverting the sealed 
tube 6 times. The lysate was then poured into the barrel of a QIAfilter Cartridge and 
allowed to incubate for another 10min at room temperature. Then, the cell lysate was 
gently filtered into a previously equilibrated QIAGEN-tip. The now cleared lysate then 
entered the resin by gravity, followed by 2 times washing of the QIAGEN-tip with 
buffer QC (10ml each wash step).  5ml of buffer QF were added to elute DNA into a 
15ml Falcon tube. 3.5ml isopropanol were applied for precipitation of DNA, followed 
by immediate mixing and centrifugation at 15000xg for 30min at 4°C. The  
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supernatant was discarded carefully and the pellet was washed with 2ml 70%  
ethanol, followed by another centrifugation at 15000xg for 10min at room  
temperature. Again the supernatant got discarded and the pellet was allowed to air 
dry for 10min. Finally the air dried pellet got resuspended in 100ml of TE buffer,  
pH 8.0.  
 
2.2.13 Control Restriction Enzyme Digestion  
 
For digestion of minipreps the following components were mixed and incubated for 
60 minutes at 37°C, gently shaking: 
3µl plasmid DNA 
1µl buffer 
0,5µl restriction enzyme 
5,5µl ddH2O 
The appropriate restriction buffer was chosen in agreement with the recommenda-
tions of the producer. The restriction digest pattern was checked by agarose gel  
electrophoresis. 
 
2.2.14 Sequence Analysis 
 
For sequence analysis, Mini or Midi - preparations of plasmid DNA were sent to 
VBC - Genomics Bioscience Research GmbH, Vienna, Austria. 
 
2.2.15. Radiolabelling of DNA Fragments 
 
To generate a radiolabelled ggSRBI probe for Northern blot analysis of total RNA, the 
Amersham Megaprime DNA labelling kit was used. 4µl purified PCR fragment diluted 
with 24µl DEPC treated H2Odd and 5µl primer (random hexamers provided by the kit) 
were combined in an Eppendorf screwcap tube. The mixture was heated to 95°C for 
5 minutes and then chilled on ice. The content was collected by short centrifugation. 
10µl labelling buffer, 2µl Klenow Polymerase (5U/µl) and finally 5µl α−32P dCTP 
(10µCi/µl; Hartmann Analytics) were added. The mixture was spun and incubated at 
37°C for 1 hour. The reaction was stopped by heatin g to 95°C for 5 minutes. The  
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labelled DNA was separated from unincorporated radioactive nucleotides by gel  
filtration using NICK columns (Pharmacia Biotech). The sample was applied to a 
Pharmacia NICK column, which was rinsed once with TE buffer. The labelled DNA 
was eluted in five 400µl fractions. Fractions were measured with a radiometer.  
According to the radio labelling protocol, radiation should be highest in fraction 2, if 
α−32P dCTPs have been incorporated into the probe DNA strands successfully. This 
fraction was then added to the prehybridized Northern blot membrane (see 2.15) 
 
2.2.16 Glyoxal Northern Blot Analysis 
 
Northern Blotting was carried out using the glyoxal gel electrophoresis method. All 
solutions were prepared with RNA grade chemicals. ddH2O was treated with DEPC 
(DEPC.ddH2O, 0.1%). For sample preparation the following components were  
pipetted into a fresh autoclaved Eppendorf reaction tube, chilled on ice: 
 
Between 10 to 30µg total RNA in 6µl ddH2O ultrapure 
11.8µl DMSO 
2.4µl 0.1 M NaHPO4 buffer 
3.5µl 40% Glyoxal 
 
Samples were incubated at 50°C for 1 hour and subse quently chilled on ice.  Finally, 
6.3µl glyoxal loading buffer were added. Marker preparation was done in analogy to 
sample preparation except the incubation step at 50°C, which was 30min of length 
and  3µl of 0.5-10Kb RNA Ladder from Invitrogen were added instead of 10 to 30µg 
total RNA. Then, samples and marker were loaded onto the agarose gel.  
A 1.2% agarose gel, 10mM NaHPO4 buffer (which was also used as running buffer) 
was prepared.  Samples and marker were loaded into the slots and the gel was run 
at 80V for 90 minutes. The direction of the gel was changed every 30 minutes to 
avoid  pH- or salt-gradients. 
After gel electrophoresis, the gel was equilibrated in Gel Wash Buffer-I for 20  
minutes, in Gel Wash Buffer-II for 20 minutes and in 10× SSC for 30 minutes at room 
temperature, gently shaking. To transfer the RNA onto a nylon membrane a blot was 
prepared as follows:  
                                                                                                 Materials and Methods                                                     
 
                                                                                                                                   37
 
A glassplate was covered with 6 Whatman papers of same size as the plate soaked 
in 20× SSC, the gel was applied upside down, followed by a nylon membrane  
(Hybond-N for nucleic acid transfer from Amersham Biosciences) and 6 dry 
Whatman papers of the size of the membrane. A package of green towels and a 
weight were placed on top of the blot, so capillary transfer could occur sufficiently. 
Blotting was carried out overnight at RT. After marking the slots of the loaded  
samples, the next day, the membrane was rinsed in 2× SSC, placed on a Whatman 
paper and crosslinked in a Stratagene UV crosslinker. 
Now RNA was stained with methyleneblue for 5 minutes and destained with DEPC 
treated H2Odd. The stained membrane was photocopied and the replica served as 
size marker for 28S and 18S rRNA, representing a loading control. 
 Then the membrane was prehybridized to block free positions on the membrane, in 
a glass roller-bottle filled with 10ml of prewarmed hybridization solution for 3 hours at 
65°C. After addition of the radiolabelled probe (se e 2.14), the blot was hybridized 
overnight at 65°C circulating. 
The next day the membrane was washed 1-2 times for 10 minutes with wash buffer A 
and 2-3 times for 10 minutes with wash buffer B, depending on the radiation intensity 
of the blot background. The washing solutions were prewarmed to 65°C. 
Finally the membrane was fixed in a film cassette and exposed to a film (Pierce,  
CL-XPosureTMFilm) at –80°C for one to several days depending on the intensity of 
the signal. 
 
1M Na-Phosphate Buffer                             Glyoxal Loading Buffer 
462mM Na2HPO4                                          50% Glycerol 
469mM NaH2PO4                                          10mM Na-Phosphate Buffer 
pH 6.8                                                              0.4% Bromophenolblue 
add DEPC treated H2Odd up to 200ml           0.25% Xylene Cyanol FF 
 
Methylenblue Staining Reagent                  Gel Wash Buffer-I 
0.04% Methylenblue                                       50mM NaOH 
0.5M NaOAc pH 5.2                                       150mM NaCl 
                                                                        DEPC treated H2Odd to a final volume                  
                                                                        of 250ml             
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20× SSC                                                       Gel Wash Buffer-II                                                      
3M NaCl                                                        100mM Tris-HCl buffer pH 7.5 
0.3M Na-Citrat                                               150mM NaCl        
pH 7,2                                                            add DEPC treated H2Odd up to 150ml      
add DEPC treated H2Odd up to 250ml               
 
Hybridization Solution                                 Membrane Wash Buffer A                            
1% BSA Fraction V                                        0.5% BSA                                                       
40% DEPC treated H2Odd                            5% SDS                                                          
7% SDS                                                         40mM Na-Phosphate buffer         
500mM Na-Phosphate Buffer pH 6.8            1mM EDTA 
1mM EDTA                                                    add DEPC treated H2Odd up to 250ml 
mixed in order shown above; final volume 
should be 10ml 
 
Membrane Wash Buffer B 
1% SDS  
40mM Na-Phosphate buffer 
1mM EDTA 
add DEPC treated H2Odd up to 500ml 
 
2.3 Protein Chemistry 
 
2.3.1 Protein Extraction 
 
2.3.1.1 Total Protein Extraction 
 
8ml ice-cold homogenization buffer and 100µl protease inhibitor cocktail were added 
to 2g freshly obtained chicken tissue, which was then homogenized with an  
Ultra-Turrax T25 homogenizer 3× for 20sec. In between the homogenization steps 
the samples were chilled on ice. The homogenates were centrifuged for 3min at 
3000×g and 4°C. The supernatant was transferred to a fre sh tube, 400µl 20% Triton 
X-100 were added and the solution was vigorously shaken. The mixture was then 
incubated at 4°C for 30 minutes and finally centrif uged at 300 000xg for 1 hour at 
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4°C. The supernatant was aliquoted and stored at –8 0°C. Protein concentration was 
determined using Bio-Rad Protein Assay (BioRad). Protease inhibitor cocktail was 
added to homogenization buffer, so proteins were not degraded. 
 
Homogenization Buffer                          Protease Inhibitor Cocktail            
20mM HEPES                                   AEBSF 104mM            1.5mM Pepstatin      
300mM sucrose                                 0.08mM Aprotinin         1.4mM E-64 
150mM sodium-chloride                    2mM Leupeptin             1ml/20g wet weight       
                                                           4mM Bestatin 
 
2.3.1.2 Membrane Protein extraction 
 
Homogenization of chicken tissue for membrane preparation was performed  
analogous to total protein extraction (see 2.3.1.1). After homogenization total 
homogenates were centrifuged at 620xg for 10min at 4°C. The supernatant was then 
transferred to a reaction tube, and 1/20 of total volume 20% Triton X-100 was added. 
The homogenates were vortexed and incubated for 30min at 4°C. After incubation 
samples were centrifuged at 300 000xg for 60min at 4°C. The resulting supernatant 
was aliquoted and stored at –80°C. Protein concentr ation was determined using  
Bio-Rad Protein Assay (BioRad). Protease inhibitor cocktail was added to 
homogenization buffer, so proteins were not degraded. 
 
             Homogenization Buffer 
20mM HEPES                       0.5mM PMSF              
300mM sucrose                    2.5µM leupeptin 
150mM sodium-chloride 
 
2.3.2 Protein Analysis 
 
2.3.2.1 SDS-PAGE 
 
Protein extracts, suspensions of bacteria expressing recombinant peptides,  ,and  
protein purification or wash fractions were analyzed by sodium dodecylsulfate  
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polyacrylamide gel electrophoresis (SDS-PAGE), followed by Coomassie staining or 
transfer of the separated proteins to a nitrocellulose membrane Western blotting of 
proteins of interest. Protein samples were mixed with Laemmli buffer (reducing or 
non-reducing). Under reducing conditions the samples were incubated for 5min at 
95°C, chilled on ice immediately, spun down in a ta ble top centrifuge and loaded onto 
a sodium dodecylsulfate polyacrylamide gel. Under non-reducing conditions samples 
mixed with Laemmli buffer were loaded as such. Stacking gels had a concentration of 
4% polyacrylamid, whereas separation gels of 10-, 12- and 14% were used. 45 to 
50µg of total and membrane protein extracts, as well as up to 20µl of recombinant 
bacterial suspensions, protein purification or wash fractions were loaded per slot. The 
gel was run at 80V until the bromophenolblue front reached the separation gel and 
then was turned to 100 -140V. 5µl Fermentas Page Ruler Prestained Protein Ladder 
Plus  were loaded as Marker.  
 
Laemmli Buffer (reducing)             Laemmli Buffer (non-reducing) 
31.2% glycerol                                  31.2% glycerol         
6% SDS                                            6% SDS  
1M Tris pH 7.5                                  1M Tris pH 7.5   
872.4mM ß-mercaptoethanol           ddH2O up to 20µl 
ddH2O up to 20µl 
 
2.3.2.2 Western Blot 
 
After SDS-PAGE the separated proteins were transferred to a nitrocellulose  
membrane (Hybond-C Extra for optimized protein transfer, Amersham Bioscience). 
This was performed in a peQlab PerfectBlue “Semi-Dry” Electro Blotter. The blot was 
prepared as follows: 
3 Whatman papers soaked in 1× Transfer buffer were applied to the blotting unit, fol-
lowed by the nitrocellulose membrane, the gel and finally 3 more wet Whatman pa-
pers. To avoid air bubbles a Falcon tube was rolled over the blot. The blot was  
covered with the lid of the blotting unit. Blotting was performed at 200mA per gel for 1 
hour at room temperature. To check transfer efficiency, the membrane was stained 
with Ponceau S for 1min. Blotted proteins and the standards were visualized by  
destaining with H2Odd. The lanes of the loaded samples were marked with a pencil 
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and excess parts of the membrane were cut off. The membrane was blocked for 
90min at 4°C with 5% nonfat dry milk in 1 × TBS-T (Tris-Buffer-Saline, 0,1%Tween) 
solution. After removing the blocking solution, the primary antibody was also diluted 
(different dilutions) in blocking solution and the membrane was incubated with this 
solution overnight at 4°C while gently shaking. The  membrane was washed 3× 5-10 
minutes in 1× TBS-T, followed by incubation with secondary antibody, which was 
conjugated with horse raddish peroxidase, diluted (1:50 000) in blocking solution. 
After 1-2 hours of incubation at room temperature under gentle shaking, the solution 
was discarded and the membrane was washed another three times with 1× TBS-T 
for 5-10 minutes. Pierce Super Signal Kit was used to visualize the proteins bound by 
the secondary antibody. The membrane was incubated with an 1:1 mixture of solu-
tion I and II for 2 minutes at room temperature and put into an exposure cassette. 
Films were exposed in the dark room from 1 min to 1 hour.  
 
2.3.2.3 Coomassie staining 
 
After SDS-PAGE the separation gel was place in a well and Coomassie Blue stain 
was added until the gel was completely covered by it. The gel was then incubated for 
45min. Then, the Coomassie Blue stain was recycled and destaining solution was 
added to the gel. After 2 hours of incubation, protein bands were well detectable and 
distinguishable, and the gel was put onto a Whatman paper and dried at 80°C for 
30min under vacuum. After drying the gel was analyzed. 
 
1× Transfer Buffer                                              Ponceau S 
25mM Tris-HCl                                                     0.2% Ponceau S 
192mM Glycine                                                    3% Trichloracetic Acid 
                                                                             dilute with 1× TBS 
10× TBS                                                                 
1.37M NaCl                                                          1× TBS-T 
0.027M KCl                                                          0.1% Tween 
0.25M Tris-HCl                                                    1× TBS 
with HCl to pH 7.4                                                pH 7.4           
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Coomassie Blue                                                    Destaining Buffer 
300ml glacial acetic aid                                          10% acetic acid       
750ml isopropanol                                                  30% methanol 
0.862g Coomassie Blue R250                                ddH2O up to 1l   
1950ml ddH2O 
 
2.4 Generation of a Specific Antibody against ggSRBI and ggSRBII 
 
2.4.1 Recombinant Peptide Expression 
 
The PCR product from laying hen chicken liver cDNA with the primer set  
ggSRBI-Fwd1-NcoI and ggSRBI-Rev1-EcoRI was cloned into the vector pET-25b(+) 
and chemically competent E.Coli BL-21 were transformed with that plasmid. These 
transformed bacterias were then used for expression of the recombinant peptide  
encoded by the ggSRBI DNA sequence amplified by the primer set mentioned 
above. After purification the recombinant peptide was then used to raise a specific 
antibody against ggSRBI and ggSRBII by immunization of a rabbit. This recombinant 
peptide consists of the encoded ggSRBI fragment, a linker amino acid region and an 
HSV- as well as a 6xHistidine tag. The latter is used for peptide purification. Before 
recombinant peptide could be used for immunization, it was necessary to check if 
induction of peptide expression was successful and which buffer would solubilize the 
peptide best. Therefore two test expressions, namely a time course for induction and 
a solubilization test, were done with less volume than the final mixture used for  
purification of enough quantity of recombinant peptide for further use in  
immunization. 
 
2.4.2 Induction Time Course  
 
A single colony from an LB-amp plate of transformed BL-21 bacterial cells was 
picked and used for inoculation of 5ml LB-amp medium. This culture was then  
incubated overnight at 37°C, shaking. 200µl of this  starting culture then were trans-
ferred into 10ml LB-amp followed by another incubation step at 37°C for 3hours, 
again shaking. Bacterial cells were allowed to grow to an optical density at 600nm of 
0.6, which was measured photometrically. Isopropyl-β-D-thiogalactopyranosid (IPTG) 
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was added to a final volume of 1mM to induce recombinant peptide expression. Be-
fore addition of IPTG, 1.5hours after induction and 3hours after induction samples of 
100µl were taken and pipetted into Eppendorf reaction tubes. These samples were 
centrifuged at 14000rpm for 1min at room temperature and the supernatant was  
discarded. Pellets were stored at –20°C. The next d ay these pellets were  
resuspended in 40µl PBS and two SDS-PAGEs (10% polyacrylamide separation 
gels)  were performed, each being loaded with 10µl of each sample. After  
SDS-PAGE, one gel was analyzed by Western Blotting and the other one by 
Coomassie Blue staining  
 
              PBS 
Sodium Chloride 137mM 
Potassium Chloride 137mM 
Na2HPO4 10mM 
KH2PO4 1.7mM 
 
2.4.3 Solubilization Test 
 
Pellets of 1ml of recombinant peptide expressing BL-21 cells in LB-amp medium,  
derived by the procedure described in 2.4.2, were resuspended in 700µl of 4 different 
types of lysis buffers. TBST, TBST/10mM Imidazol, 5M Urea/PBS Buffer and Lysis 
Buffer A were used, to check which buffer would be the best for solubilization of the 
expressed recombinant peptide. The suspensions were sonicated 3 times for 10sec, 
chilled on ice and then centrifuged at 5000rpm for 10min at 4°C. The supernatant 
was collected in a new Eppendorf reaction tube and the pellets were resuspended in 
PBS. 15µl of the suspensions and the supernatant then were analyzed by performing 
a SDS-PAGE (12%polyacrylamide separating gel), followed by Commassie Blue 
staining of the separated proteins. The ratio of recombinant peptide in the pellet frac-
tion and in the supernatant fraction for all lysis buffers was then analyzed. After  
discussing the result with Professor Dr. Wolfgang J. Schneider, TBST/10mM  
Imidazol was chosen as lysis buffer for future peptide expressions.   
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             Lysis Buffer A 
50mM Tris              0.1% TWEEN 20        
500mM NaCl          10% Glycerol   
1%Triton X-100      20mM Imidazol  
 
2.4.4 Recombinant Peptide Expression and Purification using Ni-NTA Agarose  
 
Protein expression was done analogous to point 2.4.2, but with more total volume of 
medium. 7ml overnight starter culture were added to 500ml LB-amp medium.  
Centrifugation was carried out at 6000rpm for 15min at 4°C. Due to the size of the 
centrifugation tubes it was necessary to portion the 500ml bacterial culture into two 
tubes, each 250ml of volume, before centrifugation. Pellet 2 was stored at -20°C as a 
reserve, while pellet 1 was resuspended in 6ml TBST/10mM Imidazol, except for a 
small piece of this pellet, which was stored at –20°C as control. The suspension was 
sonicated 3 times each for 30sec, chilled on ice and centrifuged at 3500rpm for 
10min at 4°C.The supernatant was transferred into a  50ml Falcon tube, 1ml Ni-NTA 
Agarose (QIAGEN) and TBST/10mM Imidazol were added to a final volume of 40ml. 
The solution was then incubated overnight at 4°C ro tating, so Ni-NTA Agarose could 
bind to soluble recombinant peptide by attaching to the 6xHis tag. The next day the 
solution was centrifuged at 3500rpm for 5min at 4°C . The supernatant was kept as 
control and the pellet was washed 4 times with TBST/10mM Imidazol. In between the 
wash steps the sample was centrifuged at 3500rpm for 5min at 4°C and the  
supernatants were kept also as controls. After the final wash step the pellet was  
resuspended in 1ml TBST/10mM Imidazol, transferred into an Eppendorf reaction 
tube and centrifuged at 6000rpm for 5min at 4°C. Th e supernatant was discarded 
and the pellet resuspended in 1ml TBST/250mM Imidazol to elute the recombinant 
peptide from the Ni-NTA Agarose. The solution was incubated at 4°C for 1hour and 
30min rotating, followed by another centrifugation at 6000rpm for 5min at 4°C. The 
supernatant named Eluate 1, which should contain the recombinant peptide, was 
transferred into a new Eppendorf reaction tube and the pellet was kept as a control. 
Efficiency of peptide purification was analyzed by SDS-PAGE under reducing  
conditions, followed by  Coomassie Blue staining of the gel. Eluate 1 was stored at  
–20°C. The pellet containing the Ni-NTA Agarose was  stored at 4°C and the next day 
another 200µl of TBST/250mM Imidazol were added. The pellet was resuspended 
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and incubated at 4°C for 2hours and 30min, rotating . The suspension was then  
centrifuged at 6000rpm for 5min at 4°C, the superna tant named Eluate 2 was stored 
at –20°C and the pellet was kept at 4°C. 
The day after the pellet was resuspended in 500µl TBST, 250mM Imidazol, 2mM 
KCL, 25mM Tri, 300mM NaCl and was incubated for 2hours and 30min at 4°C,  
rotating. The suspension was then centrifuged again at 6000rpm for 5min at 4°C and 
the supernatant named Eluate 3, was transferred to an Eppendorf reaction tube.  
These last 3 steps were done one more time. The supernatant derived from the  
second centrifugation was named Eluate 4 and both supernatants were combined as 
Eluate 3/4 and stored at –20°C. The pellet was kept  at 4°C. 
The next day Eluates 1-3/4 and the pellet containing the Ni-NTA agarose bound to 
the rest of the recombinant peptide were then analyzed by two SDS-PAGEs under 
reducing and non-reducing conditions, followed by Western Blotting and Coomassie 
Blue staining. 20µl from each Eluate and 15µl of the pellet were loaded. The pellet 
was stored at 4°C all Eluates at –20°C.  
One week later, the pellet was washed 4 times with 10ml ddH2O. In between the 
washing steps the sample was centrifuged at 3500rpm for 5min at 4°C. The  
supernatants were kept as controls. After the final wash step 550µl of 0.3M  
ammonium hydroxide were added  to completely clean the Ni-NTA Agarose and  
remove all recombinant peptide still bound. The sample was vortexed for 1min and 
then centrifuged at 6000rpm for 5min at 4°C. The su pernatant was portioned into two 
Eppendorf reaction tubes and was lyophilized in a speedvac overnight at 4°C. The 
pellet was kept at 4°C as a control. The next day t he lyophilized samples named  
Eluate 5/I and 5/II  were resuspended in 100µl reducing Laemmli buffer and stored at  
–20°C. The day after Eluate 5/I, 5/II and the pelle t were then analyzed by two  
SDS-PAGEs under reducing conditions, followed by Western Blotting and 
Coomassie Blue staining. All solutions contained protease ihnhibitor cocktail. 
 
 
 
 
 
 
Materials and Methods 
46 
2.4.5 Immunization 
 
The bacterial pellet containing the expressed recombinant peptide that had been 
stored at –20°C and was not used for purification w ith Ni-NTA Agarose kit (see 
2.4.4), was resuspended in 6ml TBST containing protease inhibitor cocktail and  
aliquoted into 1.5ml Eppendorf reaction tubes. 4 SDS-PAGEs were done under  
reducing conditions, 200µl of bacterial suspension were loaded onto each gel. The 
separated proteins were Coomassie Blue stained and and destained overnight. The 
next day the band representing the recombinant peptide at a size of ~30kDa was  
excised with a scalpel, cut into pieces, frozen in liquid nitrogen, ground with a pestle 
and finally lyophilized overnight at –55°C and 0.03 bar. The next day 400µl PBS were 
added and the lyophilized pieces were resuspended. The suspensions were kept at 
4°C unitl they were given to Ao.Univ.-Professor Dr.  Marcela Hermann, who then 
added the same volume Freud’s Adjuvans and injected rabbit 75/07 with it. This  
procedure was repeated after 3 and a half week, 5 weeks and 8 weeks. 
15ml blood were taken from the rabbit before immunization (to produce preimmune 
serum), used as negative control, 15ml 6 weeks after immunization,  50ml after 7 
weeks, 15ml after 9 weeks and finally 100ml after 11 weeks. Blood samples were 
stored at 4°C overnight and centrifuged  the next d ay at 4000rpm for 15min at 4°C. 
The supernatant immune serum was aliquoted into tubes and stored at –20°C.  
Binding specificy of the antiserum, crossreactions and dilution factor of the antiserum 
necessary for adequate results were tested by various Western Blot experiments  
under reducing and nonreducing conditions, performed with total and membrane  
protein extracts of laying hens and other species, as well as with the recombinant 
peptide itself. Antiserum used for Western Blot analysis was diluted in 5% non-fat dry 
milk, TBST and  5% non-fat dry milk, TBST, 2mMCaCl2. Different dilutions were 
tested. Preimmune serum was used as negative control, diluted 1:100 in 5% non-fat 
dry milk, TBST. 
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3 Results 
 
3.1 Cloning of ggSRBI 
 
ggSRBI mRNA sequence was derived from ENSEMBL Genome Browser (Transcript 
ID GENSCAN00000043265, ggSCRBI).  The first step of this diploma work was  
cloning full length ggSRBI and verifying the nucleotide sequence derived from  
ENSEMBL chicken database. Therefore total RNA was isolated from laying hen liver, 
in which SRBI expression is highest in humans, using NucleoSpin RNA II kit. Total 
RNA then was transcribed into cDNA, using oligo-dT primers and SUPERSCRIPT II 
reverse transcriptase. Primers were designed according to the ENSEMBL derived 
nucleotide sequence and used for PCR of chicken liver cDNA samples mentioned 
above. Using primerset ggSRBI-F1 and ggSRBI-Rev5 two PCR products of distinct 
size were obtained (Fig. 3.1.1), depending on the concentration of ggSRBI-F1. 
GgSRBI-F1 was used at a final concentration of 1µM, as well as 1nM, whereas 
ggSRBI-Rev5 was known to be most efficient at a concentration of 25nM per PCR 
approach.  
 
Fig 3.1.1 
PCR of chicken liver cDNA using primerset  
ggSRBI-F1/Rev5.  
1…1µM ggSRBI-F1 
2…1nM ggSRBI-F1 
 
Both PCR products were cloned into pCR 2.1-Topo, using a Topo TA cloning kit. 
Plasmid minipreperation followed by EcoRV restriction enzyme digestion confirmed 
PCR results. 
 
Fig. 3.1.2 
EcoRV restriction enzyme digestion 
1,2…1µM ggSRBI-F1 
3,4…1nM ggSRBI-F1  
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Sequencing of inserts 2 and 4 revealed there is no diference between the nucleotide 
sequence of insert 2 and the ENSEMBL sequence of ggSRBI (Fig. 3.1.3), concluding 
Insert 2 corresponds to full length ggSRBI.  
Insert 4 on the other hand showed no similarity with that sequence. Lower  
concentration of ggSRBI-F1, in combination with the PCR program used, seem to 
result in amplification of a completely different, unspecific PCR Product.  
 
ggSRBI_Ensembl      --------------ATGGTCGCGGCCGGGCGCAGGGTGGCGGTGGGGCTGGGGGCGGTCG 46 
Fl-ggSRBI-Rev5      GCGCTCTGCGAGCCATGGTCGCGGCCGGGCGCAGGGTGGCGGTGGGGCTGGGGGCGGTCG 60 
                    
 
        ********************************************** 
 
ggSRBI_Ensembl      GGGCCGTTTGCCTGCTGCTGGGCGGCTGCCTGCTGCTGGCGGGGCCCGCCATCGTCAAGG 106 
Fl-ggSRBI-Rev5      GGGCCGTTTGCCTGCTGCTGGGCGGCTGCCTGCTGCTGGCGGGGCCCGCCATCGTCAAGG 120 
                    ************************************************************ 
 
ggSRBI_Ensembl      AGCAGGTCCTCAAGAATGTGAGGATTGACCCCAGCAGCATCTCCTTCAACATGTGGAGGG 166 
Fl-ggSRBI-Rev5      AGCAGGTCCTCAAGAATGTGAGGATTGACCCCAGCAGCATCTCCTTCAACATGTGGAGGG 180 
                    ************************************************************ 
 
ggSRBI_Ensembl      ACATCCCTGTTCCTTTTTATCTGACGGTGAACCTCTTTGAAGTGCAGAACCCCCAAGAGG 226 
Fl-ggSRBI-Rev5      ACATCCCTGTTCCTTTTTATCTGACGGTGAACCTCTTTGAAGTGCAGAACCCCCAAGAGG 240 
                    ************************************************************ 
 
ggSRBI_Ensembl      TCCTCCAGGGAGCGAAGCCAAAGGTGAACCAGCGTGGACCGTATGTTTACAGAGAGTTCA 286 
Fl-ggSRBI-Rev5      TCCTCCAGGGAGCGAAGCCAAAGGTGAACCAGCGTGGACCGTATGTTTACAGAGAGTTCA 300 
                    ************************************************************ 
 
ggSRBI_Ensembl      AGTATAAGACAAACATCACTTTCCATGACAACGACACCGTCTCCTACCTGGAGTACCGGC 346 
Fl-ggSRBI-Rev5      AGTATAAGACAAACATCACTTTCCATGACAACGACACCGTCTCCTACCTGGAGTACCGGC 360 
                    ************************************************************ 
 
ggSRBI_Ensembl      AGCTCTTCTTCCGGCCAGACTTGTCCAACGGCACTGAAGATGAGTACATCGTGATGCCCA 406 
Fl-ggSRBI-Rev5      AGCTCTTCTTCCGGCCAGACTTGTCCAACGGCACTGAAGATGAGTACATCGTGATGCCCA 420 
                    ************************************************************ 
 
ggSRBI_Ensembl      ACATCTTGATGTTGGGAGCAGCTGTCATGATGGAAAACCTGCCTAGTTTTGTGAAGCTCT 466 
Fl-ggSRBI-Rev5      ACATCTTGATGTTGGGAGCAGCTGTCATGATGGAAAACCTGCCTAGTTTTGTGAAGCTCT 480 
                    ************************************************************ 
 
ggSRBI_Ensembl      TGCTGAGCGGGGCCCTGGCTGGCCTGAAGCAGGAGGCCTTCATAAACCGGACAGTGGGGG 526 
Fl-ggSRBI-Rev5      TGCTGAGCGGGGCCCTGGCTGGCCTGAAGCAGGAGGCCTTCATAAACCGGACAGTGGGGG 540 
                    ************************************************************ 
 
ggSRBI_Ensembl      AGATCTTGTGGGGCTATGAAGACCCTCTTTTAGACACCATAAATGCCCTTGTCCCTGGCC 586 
Fl-ggSRBI-Rev5      AGATCTTGTGGGGCTATGAAGACCCTCTTTTAGACACCATAAATGCCCTTGTCCCTGGCC 600 
                    ************************************************************ 
 
ggSRBI_Ensembl      TGATCCCATACAAGGGGAAATTTGGCATATTTATAGAGTTTAACAACACCAATTCTGGAT 646 
Fl-ggSRBI-Rev5      TGATCCCATACAAGGGGAAATTTGGCATATTTATAGAGTTTAACAACACCAATTCTGGAT 660 
                    ************************************************************ 
 
ggSRBI_Ensembl      TGTTCACAGTGAACACAGGCATGAAGAACATCAGTCAAGTTCATATGGTGGATTCATGGA 706 
Fl-ggSRBI-Rev5      TGTTCACAGTGAACACAGGCATGAAGAACATCAGTCAAGTTCATATGGTGGATTCATGGA 720 
                    ************************************************************ 
 
ggSRBI_Ensembl      ATGGCTTGAAAAAGGTGAACTACTGGCGGACCAATGAGTGCAACATGATCAATGGGACTG 766 
Fl-ggSRBI-Rev5      ATGGCTTGAAAAAGGTGAACTACTGGCGGACCAATGAGTGCAACATGATCAATGGGACTG 780 
                    ************************************************************ 
ggSRBI_Ensembl      CAGGGGAGATGTGGCCACCGTATATGTCCCCAACATCGCTGGAGTTCTACAGCCCCGATG 826 
Fl-ggSRBI-Rev5      CAGGGGAGATGTGGCCACCGTATATGTCCCCAACATCGCTGGAGTTCTACAGCCCCGATG 840 
                    ************************************************************ 
 
ggSRBI_Ensembl      CCTGCAGATCCATGACACTGGTGTACGAGCAGTCGGGGAAATTCAAGGGTGTGCCCACCT 886 
Fl-ggSRBI-Rev5      CCTGCAGATCCATGACACTGGTGTACGAGCAGTCGGGGAAATTCAAGGGTGTGCCCACCT 900 
                    ************************************************************ 
 
ggSRBI_Ensembl      ATCGCTTTGTGGCACCGAAAACTCTCTTTGCCAATGGCACAGATTATCCCCCCAACGAAG 946 
Fl-ggSRBI-Rev5      ATCGCTTTGTGGCACCGAAAACTCTCTTTGCCAATGGCACAGATTATCCCCCCAACGAAG 960 
                    ************************************************************ 
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The PCR product of ggSRBI-F1/Rev5 is of a length of 1580bp and contains an 
1512bp open reading frame, coding for ggSRBI protein (Fig.3.1.4). 
 
  
 
 
 
 
Fig. 3.1.3 Alignment of ggSRBI nucleotide sequence derived from ENSMBL and 
PCR of chicken liver cDNA using primerset ggSRBI-F1/Rev5.  
Red…Primers 
Blue…Start and stop of translation 
ggSRBI_Ensembl      GCTTCTGTCCCTGCAGGCAATCCGGCATCCAGAACGTCAGCTCCTGCAGGCTGAATGCAC 1006 
Fl-ggSRBI-Rev5      GCTTCTGTCCCTGCAGGCAATCCGGCATCCAGAACGTCAGCTCCTGCAGGCTGAATGCAC 1020 
                    ************************************************************ 
 
ggSRBI_Ensembl      CAATGTTCATCTCCCACCCTCACTTCTACAATGCTGACCCAAGCCTGGTGGATGCTGTGG 1066 
Fl-ggSRBI-Rev5      CAATGTTCATCTCCCACCCTCACTTCTACAATGCTGACCCAAGCCTGGTGGATGCTGTGG 1080 
                    ************************************************************ 
 
ggSRBI_Ensembl      AAGGCCTGCACCCCAGCAGGGAGGAGCACGCGCTCTTCCTCGATGTGCACCCGGTGACAG 1126 
Fl-ggSRBI-Rev5      AAGGCCTGCACCCCAGCAGGGAGGAGCACGCGCTCTTCCTCGATGTGCACCCGGTGACAG 1140 
                    ************************************************************ 
 
ggSRBI_Ensembl      GCATCCCCATGAACTGCTCCATCAAGCTCCAGCTGAACCAGTACATGAAGCAGGTGTCTG 1186 
Fl-ggSRBI-Rev5      GCATCCCCATGAACTGCTCCATCAAGCTCCAGCTGAACCAGTACATGAAGCAGGTGTCTG 1200 
                    ************************************************************ 
 
ggSRBI_Ensembl      GTATCCTTCAAACAGGGAAGATTCAGCCTGTGGTGATGCCGCTGCTGTGGTTTGCAGAGA 1246 
Fl-ggSRBI-Rev5      GTATCCTTCAAACAGGGAAGATTCAGCCTGTGGTGATGCCGCTGCTGTGGTTTGCAGAGA 1260 
                    ************************************************************ 
 
ggSRBI_Ensembl      GTGGATACATTGATGGCTCAGTCCTATCGCAGTTTTACACCAACCTGGTGCTGATCCCAT 1306 
Fl-ggSRBI-Rev5      GTGGATACATTGATGGCTCAGTCCTATCGCAGTTTTACACCAACCTGGTGCTGATCCCAT 1320 
                    ************************************************************ 
 
ggSRBI_Ensembl      CCATCCTAGACTACCTGCAGTACATCTTCCTCGGGCTCAGCGTCCCGCTCATCATCTCAG 1366 
Fl-ggSRBI-Rev5      CCATCCTAGACTACCTGCAGTACATCTTCCTCGGGCTCAGCGTCCCGCTCATCATCTCAG 1380 
                    ************************************************************ 
 
ggSRBI_Ensembl      CTGCACTCGTGATGATGAGTCAGAAGTCCTCCAAGGAGAAGCACCCACACGACCCCACCA 1426 
Fl-ggSRBI-Rev5      CTGCACTCGTGATGATGAGTCAGAAGTCCTCCAAGGAGAAGCACCCACACGACCCCACCA 1440 
                    ************************************************************ 
 
ggSRBI_Ensembl      CGCAGAGCCCCCCACCCCAGCCCTCCGAGACCACACCGCTCCTCCAGGACACCGGCACAC 1486 
Fl-ggSRBI-Rev5      CGCAGAGCCCCCCACCCCAGCCCTCCGAGACCACACCGCTCCTCCAGGACACCGGCACAC 1500 
                    ************************************************************ 
 
ggSRBI_Ensembl      AGAGCCAGGACACCGCCGAGGCCTGA---------------------------------- 1512 
Fl-ggSRBI-Rev5      AGAGCCAGGACACCGCCGAGGCCTGAGCTTGGGATGGGAACTGCTTCAGATCACCACCAG 1560 
                    **************************                                   
                                  
 
 
ggSRBI_Ensembl      -------------------- 
Fl-ggSRBI-Rev5      TCTCCAGAAGGGGACGTGTC 1580 
      1  M  V  A  A  G  R  R  V  A  V  G  L  G  A  V  G  A  V  C  L  20      
      1 atggtcgcggccgggcgcagggtggcggtggggctgggggcggtcggggccgtttgcctg 60      
 
     21  L  L  G  G  C  L  L  L  A  G  P  A  I  V  K  E  Q  V  L  K  40      
     61 ctgctgggcggctgcctgctgctggcggggcccgccatcgtcaaggagcaggtcctcaag 120     
 
     41  N  V  R  I  D  P  S  S  I  S  F  N  M  W  R  D  I  P  V  P  60      
    121 aatgtgaggattgaccccagcagcatctccttcaacatgtggagggacatccctgttcct 180     
 
     61  F  Y  L  T  V  N  L  F  E  V  Q  N  P  Q  E  V  L  Q  G  A  80      
    181 ttttatctgacggtgaacctctttgaagtgcagaacccccaagaggtcctccagggagcg 240     
 
     81  K  P  K  V  N  Q  R  G  P  Y  V  Y  R  E  F  K  Y  K  T  N  100     
    241 aagccaaaggtgaaccagcgtggaccgtatgtttacagagagttcaagtataagacaaac 300     
 
Results 
50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
      
 
 
 
 
        Fig. 3.1.4 Alignment of ggSRBI cDNA nucleotide- and ggSRBI protein amino  
        acid sequence. 
 
 
 
    101  I  T  F  H  D  N  D  T  V  S  Y  L  E  Y  R  Q  L  F  F  R  120     
    301 atcactttccatgacaacgacaccgtctcctacctggagtaccggcagctcttcttccgg 360     
 
    121  P  D  L  S  N  G  T  E  D  E  Y  I  V  M  P  N  I  L  M  L  140     
    361 ccagacttgtccaacggcactgaagatgagtacatcgtgatgcccaacatcttgatgttg 420     
 
    141  G  A  A  V  M  M  E  N  L  P  S  F  V  K  L  L  L  S  G  A  160     
    421 ggagcagctgtcatgatggaaaacctgcctagttttgtgaagctcttgctgagcggggcc 480     
 
    161  L  A  G  L  K  Q  E  A  F  I  N  R  T  V  G  E  I  L  W  G  180     
    481 ctggctggcctgaagcaggaggccttcataaaccggacagtgggggagatcttgtggggc 540     
 
    181  Y  E  D  P  L  L  D  T  I  N  A  L  V  P  G  L  I  P  Y  K  200     
    541 tatgaagaccctcttttagacaccataaatgcccttgtccctggcctgatcccatacaag 600     
 
    201  G  K  F  G  I  F  I  E  F  N  N  T  N  S  G  L  F  T  V  N  220     
    601 gggaaatttggcatatttatagagtttaacaacaccaattctggattgttcacagtgaac 660     
 
    221  T  G  M  K  N  I  S  Q  V  H  M  V  D  S  W  N  G  L  K  K  240     
    661 acaggcatgaagaacatcagtcaagttcatatggtggattcatggaatggcttgaaaaag 720     
 
    241  V  N  Y  W  R  T  N  E  C  N  M  I  N  G  T  A  G  E  M  W  260     
    721 gtgaactactggcggaccaatgagtgcaacatgatcaatgggactgcaggggagatgtgg 780     
 
    261  P  P  Y  M  S  P  T  S  L  E  F  Y  S  P  D  A  C  R  S  M  280     
    781 ccaccgtatatgtccccaacatcgctggagttctacagccccgatgcctgcagatccatg 840     
 
    281  T  L  V  Y  E  Q  S  G  K  F  K  G  V  P  T  Y  R  F  V  A  300     
    841 acactggtgtacgagcagtcggggaaattcaagggtgtgcccacctatcgctttgtggca 900     
 
    301  P  K  T  L  F  A  N  G  T  D  Y  P  P  N  E  G  F  C  P  C  320     
    901 ccgaaaactctctttgccaatggcacagattatccccccaacgaaggcttctgtccctgc 960     
 
    321  R  Q  S  G  I  Q  N  V  S  S  C  R  L  N  A  P  M  F  I  S  340     
    961 aggcaatccggcatccagaacgtcagctcctgcaggctgaatgcaccaatgttcatctcc 1020    
 
    341  H  P  H  F  Y  N  A  D  P  S  L  V  D  A  V  E  G  L  H  P  360     
   1021 caccctcacttctacaatgctgacccaagcctggtggatgctgtggaaggcctgcacccc 1080    
 
    361  S  R  E  E  H  A  L  F  L  D  V  H  P  V  T  G  I  P  M  N  380     
   1081 agcagggaggagcacgcgctcttcctcgatgtgcacccggtgacaggcatccccatgaac 1140    
 
    381  C  S  I  K  L  Q  L  N  Q  Y  M  K  Q  V  S  G  I  L  Q  T  400     
   1141 tgctccatcaagctccagctgaaccagtacatgaagcaggtgtctggtatccttcaaaca 1200    
 
    401  G  K  I  Q  P  V  V  M  P  L  L  W  F  A  E  S  G  Y  I  D  420     
   1201 gggaagattcagcctgtggtgatgccgctgctgtggtttgcagagagtggatacattgat 1260    
 
    421  G  S  V  L  S  Q  F  Y  T  N  L  V  L  I  P  S  I  L  D  Y  440     
   1261 ggctcagtcctatcgcagttttacaccaacctggtgctgatcccatccatcctagactac 1320    
 
    441  L  Q  Y  I  F  L  G  L  S  V  P  L  I  I  S  A  A  L  V  M  460     
   1321 ctgcagtacatcttcctcgggctcagcgtcccgctcatcatctcagctgcactcgtgatg 1380    
 
    461  M  S  Q  K  S  S  K  E  K  H  P  H  D  P  T  T  Q  S  P  P  480     
   1381 atgagtcagaagtcctccaaggagaagcacccacacgaccccaccacgcagagcccccca 1440    
 
    481  P  Q  P  S  E  T  T  P  L  L  Q  D  T  G  T  Q  S  Q  D  T  500     
   1441 ccccagccctccgagaccacaccgctcctccaggacaccggcacacagagccaggacacc 1500    
 
    501  A  E  A  *  504     
   1501 gccgaggcctga 1512    
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3.2 Gene Expression of ggSRBI at the mRNA Level 
 
For investigation of genexpression and tissue distribution of ggSRBI at the mRNA 
level, various Northern blots were performed.  According to ENSEMBL database 
ggSRBI mRNA consists of 1821 nucleotides. The PCR products of primer sets 
ggSRBI-fwd4/Rev4 (1330bp) and ggSRBI-Fwd1/Rev1 (704bp) (Fig. 3.2.1) were used 
as radiolabelled probes. For optimization of amplification output plasmid  
minipreperations of ggSRBI-fwd4/Rev4 and ggSRBI-Fwd1/Rev1, derived from  
RT-PCR of laying hen liver total RNA, cloned into pCR 2.1-Topo were used as tem-
plate.  For exclusion of PCR derived sequence errors, these minipreperations were 
sequenced before being used as templates. 
   Fig. 3.2.1 Nucleotide sequence of ggSRBI. Primer sets used for generation of 
   radiolabelled probes for Northern blot analysis are marked in green  
   (ggSRBI-Fwd4/Rev4) and red (ggSRBI-Fwd1/Rev1). 
Before performing Northern blots for all chicken tissues, functionality of the probes 
used had to be tested. Thus, only tissues known to show high expression levels of 
ggSRBI mRNA were used.  Total RNA was isolated from laying hen chicken tissues, 
using TRI reagent. The first Northern blot approach was performed for each 30µg of 
laying hen liver and small intestine total RNA. Methylene blue staining of the  
membrane (Fig. 3.2.2) served as loading- and quality of RNA control.  
atggtcgcggccgggcgcagggtggcggtggggctgggggcggtcggggccgtttgcctgctgctgggcggctgcctgct 80 
gctggcggggcccgccatcgtcaaggagcaggtcctcaagaatgtgaggattgaccccagcagcatctccttcaacatgt 160 
ggagggacatccctgttcctttttatctgacggtgaacctctttgaagtgcagaacccccaagaggtcctccagggagcg 240 
aagccaaaggtgaaccagcgtggaccgtatgtttacagagagttcaagtataagacaaacatcactttccatgacaacga 320 
caccgtctcctacctggagtaccggcagctcttcttccggccagacttgtccaacggcactgaagatgagtacatcgtga 400 
tgcccaacatcttgatgttgggagcagctgtcatgatggaaaacctgcctagttttgtgaagctcttgctgagcggggcc 480 
ctggctggcctgaagcaggaggccttcataaaccggacagtgggggagatcttgtggggctatgaagaccctcttttaga 560 
caccataaatgcccttgtccctggcctgatcccatacaaggggaaatttggcatatttatagagtttaacaacaccaatt 640 
ctggattgttcacagtgaacacaggcatgaagaacatcagtcaagttcatatggtggattcatggaatggcttgaaaaag 720 
gtgaactactggcggaccaatgagtgcaacatgatcaatgggactgcaggggagatgtggccaccgtatatgtccccaac 800 
atcgctggagttctacagccccgatgcctgcagatccatgacactggtgtacgagcagtcggggaaattcaagggtgtgc 880 
ccacctatcgctttgtggcaccgaaaactctctttgccaatggcacagattatccccccaacgaaggcttctgtccctgc 960 
aggcaatccggcatccagaacgtcagctcctgcaggctgaatgcaccaatgttcatctcccaccctcacttctacaatgc 1040 
tgacccaagcctggtggatgctgtggaaggcctgcaccccagcagggaggagcacgcgctcttcctcgatgtgcacccgg 1120 
tgacaggcatccccatgaactgctccatcaagctccagctgaaccagtacatgaagcaggtgtctggtatccttcaaaca 1200 
gggaagattcagcctgtggtgatgccgctgctgtggtttgcagagagtggatacattgatggctcagtcctatcgcagtt 1280  
ttacaccaacctggtgctgatcccatccatcctagactacctgcagtacatcttcctcgggctcagcgtcccgctcatca 1360 
tctcagctgcactcgtgatgatgagtcagaagtcctccaaggagaagcacccacacgaccccaccacgcagagcccccca 1440 
ccccagccctccgagaccacaccgctcctccaggacaccggcacacagagccaggacaccgccgaggcctga         1512           
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Fig. 3.2.1 
Methylene blue staining of Northern blot membrane 
1…30µg liver total RNA 
2…30µg small intestine total RNA 
 
 
 
 
 
Radiolabelled PCR product of ggSRBI-Fwd4/Rev4 was used as hybridization probe 
and films were exposed to the membrane for 1day (d), 2d and 4d (Fig. 3.2.3). 
 
  
 
 
 
 
   
    
 
 
 
Fig. 3.2.2 Northern Blot of laying hen tissues total RNA, using PCR product of 
ggSRBI-Fwd4/Rev4 as probe.  1…Liver, 2…Small Intestine  
 
Hybridization did not work properly. Most of the probe seemed to have bound to the 
marker lane, whereas there was no signal detectable in liver, even though SRBI  
expression levels are supposed to be highest in liver. In small intestine a signal was 
detected, corresponding to the size of gSRBI predicted by ENSEMBL, but still there 
occurred plenty of unspecific binding, so no certain conclusion could be drawn. 
Probably the SRBI RNA was degraded. Thus new RNA was isolated from laying hen 
liver and  adrenals, which are known to show the highest expression levels of SRBI 
per gram tissue, and another Northern blot was performed. 
 
1d exposure 2d exposure 4d exposure 
Possible Signal of 
ggSRBI-Fwd4/Rev4 
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This time, 16µg total RNA of each tissue were applied for Northern blotting. Again 
PCR product of ggSRBI-Fwd4/Rev4 was used as radiolabelled probe, but also a 
positive control was introduced, using a chicken-apoAV probe, kindly donated by  
Dr. Andrea Dichlberger. If hybridization worked out, apoAV mRNA should become 
visible as double band at 2300kb and 1430kb. Total RNAs for both approaches were 
loaded onto an agarose gel, run together, transferred to the nylon membrane and 
methylene blue stained (Fig. 3.2.3).  
 
 
 
 
 
 
 
 
 
After staining the membrane was cut into two pieces, each consisting of a  
marker-, liver- and  adrenals total RNA lane. These two membrane pieces then were 
analogly treated for hybridization, using the apoAV or the ggSRBI probe (3.2.4) and  
films were exposed to the membranes for 2d and 3d. 
 
 
 
 
 
 
 
 
Fig. 3.2.4 Northern Blot of 
laying hen chicken total 
RNA, using PCR product of ggSRBI-Fwd4/Rev4 as probe and apoAV as positive 
control. 1…Empty, 2…Liver, 3…Adrenals 
A…apoAV / 3d exposure, B…ggSRBI/ 2d exposure, C…ggSRBI/3d exposure 
Fig. 3.2.3 
Methylene blue staining of Northern blot membrane 
1,6…empty 
2,5…16µg liver total RNA 
3,4…16µg adrenals total RNA 
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The positive control worked very well. Two distinct signals were detected in liver total 
RNA corresponding to the predicted size of apoAV mRNA (2300kb, 1821kb). The 
signal at ~2300 was very sharp, whereas the signal at ~1800kb was more smudgy, 
consistent with former experiments of Dr. Andrea Dichlberger.  As the positive control 
resulted in detectable signals, RNA was of proper quality and no methodogical error 
had occurred.  Also no radiolabelled probe had bound to the marker lane. But in case 
of ggSRBI-Fwd4/Rev4, again most of the probe was bound by the marker and there 
was neither a specific signal in adrenals nor in liver.  
As the problem had not been RNA quality and probe-binding of the marker seemed 
to be probe specific, therefore another Northern blot approach was performed, 
including PCR products of ggSRBI-Fwd4/Rev4, as well as ggSRBI-Fwd1/Rev1 as 
radiolabelled probes for ggSRBI mRNA detection and again apoAV as positive 
control.   
24,6µg of laying hen liver total RNA per approach were loaded onto the agarose gel. 
Northern blot analysis was performed as described above. Methylene blue staining 
again served as loading control (Fig.3.2.6).  
 
 
Fig. 3.2.6 Methylene blue staining of Northern blot 
membrane 
 1,3,5…Empty, 2,4,,6…24,6µg liver total RNA 
 
 
 
 
 
 
GgSRBI and apoAV probes were used for hybridization and photosensitive films 
were exposed for 2d (Fig. 3.2.7)  
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Fig. 3.2.7 Northern Blot of laying hen chicken liver total RNA, using PCR products of 
ggSRBI-Fwd4/Rev4 and ggSRBI-Fwd1/Rev1 as probe, as well as apoAV as positive 
control. Films exposed for 2d. 
A…ggSRBI-Fwd4/Rev4, B…ggSRBI-Fwd1/Rev1, C…apoAV 
1…Empty, 2…Liver 
Just like before, positive control worked very well and ggSRBI-Fwd4/Rev4  
radiolabelled probe was bound to the marker. No signal was detected in liver total 
RNA. In contrast ggSRBI-Fwd1/Rev1 radiolabelled probe didn´t bind to the marker, 
but there also was no signal detected in liver. In case of  
ggSRBI-Fwd1/Rev1, obviously no binding at all had occurred. Therefore the  
membrane was incubated with radiolabelled ggSRBI-Fwd1/Rev1 again, but under 
less stringent hybridization conditions. Hybridization temperature was lowered from 
65°C to 60°C (Fig. 3.2.8).  
Fig. 3.2.8 
Northern Blot of laying hen chicken liver total RNA, using PCR 
product of ggSRBI-Fwd1/Rev1 as probe. Hybridization was  
performed at 60°C. Film was exposed to the Northern  blot  
membrane for 5d. 
1…Empty 
2…Liver 
 
Even though the probe did not bind to the marker, again no signal could be detected 
in liver.  
apoAV 
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3.3. Generation of an anti-ggSRBI Peptide Antibody 
 
For further experiments an antibody against ggSRBI was raised. Therefore a  
fragment of ggSRBI of a length of 704bp (Fig. 3.3.1) was cloned into pET-25b(+), 
using primer set ggSRBI-Fwd1-NcoI/Rev1-EcoRI for PCR and expressed  
recombinantly in chemically competent E.Coli. This peptide (Fig. 3.3.2), with a  
predicted molecular weight of 31,26 kDa then was used for immunization of a rabbit. 
Fig.3.3.1 Nucleotide alignment of ggSRBI cDNA and the PCR product of the primer 
set ggSRBI-Fwd1-NcoI/Rev1-EcoRI (marked in red).  
 
                                                                                     
ggSRBI                    CTGCTGGGCGGCTGCCTGCTGCTGGCGGGGCCCGCCATCGTCAAGGAGCAGGTCCTCAAG 120 
NcoI-Fwd1/Rev1-EcoRI      -----------------------------------------------------TACCATG 7 
                                                                                  ** * 
 
ggSRBI                    AATGTGAGGATTGACCCCAGCAGCATCTCCTTCAACATGTGGAGGGACATCCCTGTTCCT 180 
NcoI-Fwd1/Rev1-EcoRI      GATGTGAGGATTGACCCCAGCAGCATCTCCTTCAACATGTGGAGGGACATCCCTGTTCCT 67 
                           *********************************************************** 
 
ggSRBI                    TTTTATCTGACGGTGAACCTCTTTGAAGTGCAGAACCCCCAAGAGGTCCTCCAGGGAGCG 240 
NcoI-Fwd1/Rev1-EcoRI      TTTTATCTGACGGTGAACCTCTTTGAAGTGCAGAACCCCCAAGAGGTCCTCCAGGGAGCG 127 
                          ************************************************************ 
 
ggSRBI                    AAGCCAAAGGTGAACCAGCGTGGACCGTATGTTTACAGAGAGTTCAAGTATAAGACAAAC 300 
NcoI-Fwd1/Rev1-EcoRI      AAGCCAAAGGTGAACCAGCGTGGACCGTATGTTTACAGAGAGTTCAAGTATAAGACAAAC 187 
                          ************************************************************ 
 
ggSRBI                    ATCACTTTCCATGACAACGACACCGTCTCCTACCTGGAGTACCGGCAGCTCTTCTTCCGG 360 
NcoI-Fwd1/Rev1-EcoRI      ATCACTTTCCATGACAACGACACCGTCTCCTACCTGGAGTACCGGCAGCTCTTCTTCCGG 247 
                          ************************************************************ 
 
ggSRBI                    CCAGACTTGTCCAACGGCACTGAAGATGAGTACATCGTGATGCCCAACATCTTGATGTTG 420 
NcoI-Fwd1/Rev1-EcoRI      CCAGACTTGTCCAACGGCACTGAAGATGAGTACATCGTGATGCCCAACATCTTGATGTTG 307 
                          ************************************************************ 
 
ggSRBI                    GGAGCAGCTGTCATGATGGAAAACCTGCCTAGTTTTGTGAAGCTCTTGCTGAGCGGGGCC 480 
NcoI-Fwd1/Rev1-EcoRI      GGAGCAGCTGTCATGATGGAAAACCTGCCTAGTTTTGTGAAGCTCTTGCTGAGCGGGGCC 367 
                          ************************************************************ 
 
ggSRBI                    CTGGCTGGCCTGAAGCAGGAGGCCTTCATAAACCGGACAGTGGGGGAGATCTTGTGGGGC 540 
NcoI-Fwd1/Rev1-EcoRI      CTGGCTGGCCTGAAGCAGGAGGCCTTCATAAACCGGACAGTGGGGGAGATCTTGTGGGGC 427 
                          ************************************************************ 
 
ggSRBI                    TATGAAGACCCTCTTTTAGACACCATAAATGCCCTTGTCCCTGGCCTGATCCCATACAAG 600 
NcoI-Fwd1/Rev1-EcoRI      TATGAAGACCCTCTTTTAGACACCATAAATGCCCTTGTCCCTGGCCTGATCCCATACAAG 487 
                          ************************************************************ 
 
ggSRBI                    GGGAAATTTGGCATATTTATAGAGTTTAACAACACCAATTCTGGATTGTTCACAGTGAAC 660 
NcoI-Fwd1/Rev1-EcoRI      GGGAAATTTGGCATATTTATAGAGTTTAACAACACCAATTCTGGATTGTTCACAGTGAAC 547 
                          ************************************************************ 
 
ggSRBI                    ACAGGCATGAAGAACATCAGTCAAGTTCATATGGTGGATTCATGGAATGGCTTGAAAAAG 720 
NcoI-Fwd1/Rev1-EcoRI      ACAGGCATGAAGAACATCAGTCAAGTTCATATGGTGGATTCATGGAATGGCTTGAAAAAG 607 
                          ************************************************************ 
 
ggSRBI                    GTGAACTACTGGCGGACCAATGAGTGCAACATGATCAATGGGACTGCAGGGGAGATGTGG 780 
NcoI-Fwd1/Rev1-EcoRI      GTGAACTACTGGCGGACCAATGAGTGCAACATGATCAATGGGACTGCAGGGGAGATGTGG 667 
                          ************************************************************ 
 
ggSRBI                    CCACCGTATATGTCCCCAACATCGCTGGAGTTCTACAGCCCCGATGCCTGCAGATCCATG 840 
NcoI-Fwd1/Rev1-EcoRI      CCACCGTATATGTCCCCAACATCGCTGGAGTTCTACAGCCCCGATGCCAAGA-ATTCAT- 725 
                          ************************************************   * ** ***  
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0h 1,5h 3h 
Time after 
 induction 
Induced recombinant peptide 
reducing non-reducing 
Fig 3.3.2 Amino acid sequence of the recombinant peptide used for immunization. 
Cloned ggSRBI fragment is marked in red (ggSRBI-Fwd1-ncoI/Rev1-EcoRI), HSV 
tag and 6xHis tag of pET-25b(+) in green and blue. The predicted molecular weight 
for this peptide is 31,26kDa.  
As predicted, induction of  E.Coli, transformed with the construct mentioned above, 
resulted in an increase of a peptide with a molecular weight of ~32kDa (Fig. 3.3.3) 
Fig. 3.3.3 Induction time course of E.Coli transformed with ggSRBI-Fwd1-ncoI/Rev1-
EcoRI pET 25b(+). Coomassie staining. 
1,2,3… Aliquotes of transformed bacterial 
cultures 
 
    
  
 
 
Purification of the recombinant peptide should be carried out, using Ni-NTA Agarose 
(Fig. 3.3.4).  
 
 Fig. 3.3.4 
Ni-NTA Agarose purification of recombinantly 
epxressed ggSRBI-Fwd1-ncoI/Rev1-EcoRI. 
Coomassie staining. 1/6,2/7,3/8,…Aliquotes of 
eluats from different elution steps (see 2.4.4); 
4,9…Ni-NTA Agarose after all elution steps. 
Even multiple elution and wash steps (see 2.4.4) were not able to elute the recombi-
nant peptide from the Ni-NTA Agarose completely. Once bound to it, most of the re-
combinant peptide stayed within the Agarose. Thus, the peptide was used for immu-
nization without further purification (see 2.4.5). Immune sera of all 4 bleedings of the 
immunized rabbit were tested by performing Western blots of laying hen chicken liver 
MDVRIDPSSISFNMWRDIPVPFYLTVNLFEVQNPQEVLQGAKPKVNQRGPYVYREFKYKT-
NITFHDNDTVSYLEYRQLFFRPDLSNGTEDEYIVMPNILMLGAAVMMENLPSFVKLLLSGA-
LAGLKQEAFINRTVGEILWGYEDPLLDTINALVPGLIPYKGKFGI-
FIEFNNTNSGLFTVNTGMKNISQVHMVDSWNGLKKVNYWRTNECNMINGTAGEMWP-
PYMSPTSLEFYSPDAKNSSSVDKAAALEIKRASEPELAPEDPEDVEHHHHHH 
       M    1   2    3    1    2    3    1     2    3   
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total protein extracts, using the sera as primary antibody. According to the ENSEMBL 
database, ggSRBI has a predicted molecular weight of ~56kDa. Human SRBI has a 
molecular weight of 57kDa, but is heavily glycosylated and migrates on SDS gels 
at82kDa. Glycosylation status of ggSRBI was not  known at the time of these ex-
periments. The four sera visualized bands corresponding to a molecular weight of 
~64kDa in laying hen liver total protein extracts, which were not present when pre-
immune serum was used.  (Fig. 3.3.5).  
Fig. 3.3.5 
Western Blot (reducing conditions, mercaptoethanol), of  
laying hen liver total protein extracts (45µg per lane), using 
sera 1-4 as primary antibody diluted 1:500 in blocking  
solution (TBST, 2mMCaCl2, 5% milk). Film exposure 2sec. 
1…Serum 1; 2…Serum 2 
3…Serum 3; 4…Serum 4   
5...Pre-immune serum (1:100)       
 
Subsquently serum 4 was tested for detection efficiency at different concentrations  
(Fig. 3.3.6). 
Fig. 3.3.6 
Western Blot (reducing conditions, mercaptoethanol), of  
laying hen liver total protein extracts (45µg per lane), using 
different dilutions of serum 4 in blocking solution as primary 
antibody. Film exposure 2sec. 
1…1:100 
2…1:500 
3…1:1000 
4…Pre-immune serum (1:100)  
Again a band of ~64kDa was detected and according to the dilution factor of the  
primary antibody, signal intensity changed.  
Results of those two experiments indicate immunization did work out very well and 
immunomactive sera of bleeding 1-4 are suitable for detection of ggSRBI. Therefore 
these sera were named rabbit (rb) anti-ggSRBI. For further investigations some 
Western blots were performed under reducing and non-reducing conditions (Fig. 
3.3.7) 
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 red.       non-red.  
Fig. 3.3.7 
Western Blot of laying hen liver total protein extracts 
(45µg per lane) using rb-anti-ggSRBI as primary  
antibody. Film exposure 10sec. 
1,5… rb-anti-ggSRBI (1:500) 
 2,6…rb-anti-ggSRBI (1:1000)  
3,7…Pre-immune serum (1:500) 
4…Empty 
Reducing conditions resulted in the same ~64kDa bands as usual, whereas under 
non-reducing conditions the ~64kDa band almost disappear. Instead bands of other 
size became visible. 
 
In further Wester blot experiments, so called competition assays (Fig. 3.3.8), 20µl of 
the solution of the recombinant peptide, used for immunization, were added  as  
competitor to rb-anti-ggSRBI. In these experiments recombinant peptide solutions 
were supposed to compete for total protein extract ggSRBI binding to rb-anti-ggSRBI.  
 
Fig. 3.3.8 
Competition assay with rb-anti-ggSRBI  
45µg laying hen  total liver protein extract per lane 
Film exposure 20sec 
1…rb-anti-ggSRBI;  -competitor 
2…rb-anti-ggSRBI; +competitor 
3…Pre-immune serum; -competitor 
4…Pre-immune serum; +competitor 
20µl bacterial solution expressing recombinant ggSRBI-Fwd1-ncoI/Rev1-EcoRI, used 
for immunizaiton of rabbit 75/07, were used as competitor. 
Surprisingly addition of recombinant peptide, used for immunization, to  
rb-anti-ggSRBI resulted in an increase in laying hen chicken liver total protein extract 
specific ggSRBI Western blot signal intensity. Pre-immune serum activity was not 
influenced by the competitor at all.  
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As these results indicated a specific binding of rb-anti-ggSRBI to ggSRBI, the next 
question of interest was if rb-anti-ggSRBI would be functional for other species too. 
Therefore further Western blot experiments using rb-anti-ggSRBI as primary  
antibody, were performed on laying hen, mouse and quail liver total protein extracts. 
These type of Western blots were named zoo blot (Fig. 3.3.9) and performed under 
reducing (mercaptoethanol) and non-reducing conditions. 
 
Fig.3.3.9 
Zoo blot with rb-anit-ggSRBI 
45µg of total liver protein extract per lane 
1,6…Laying hen chicken 
2,7…Quail 
3,8…Mouse 
4,5…Empty 
Under reducing conditions distinct signals corresponding to similar molecular weights 
were detected for all three species. The molecular weight these bands corresponded 
to was ~64kDa for laying hen, ~67kDa for quail, and ~61kDa for mouse. Under  
non- reducing conditions the signals in quail liver and laying hen liver almost  
disappeared, whereas the intensity of mouse signal was not altered. These results 
possibly indicate a binding specifity of rb-anti-ggSRBI for SRBI in a broad variety of  
species.  
 
3.4 Isoformsearch for ggSRBII 
 
Before this work, nothing was known about SRB isoform SRBII in chicken. Both  
isoforms have been identified in other species like humans, cows, pigs, rats or mice. 
Thus, an investigation of the chicken genome for that isoform seemed worthy.  
Therefore a nucleotide alignment (Fig.3.4.1) of already known SRBII cDNA  
sequences was performed for identification of homology domains in the alternative 
exon of SRBII. These homology domains then should be used as target sequences 
for the reverse primer. Forward primer was set upstream of exon 13, where SRBI 
and SRBII sequences are identical (Fig.3.4.2).  
red. non-red. 
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PCR Program 1 2 
Fig. 3.4.1 Nucleotide alignment of mouse, rat, human and bovine SRBII cDNA. 
Primer ggSRBII-Rev1, positioned in a higly homolog domain of these orthologs, is 
marked in red. The begin of the alternative exon of SRBII is marked in blue.  
Fig. 3.4.2 Nucleotide sequence of ggSRBI. Primer ggSRBII-Fwd 1 is marked in red 
and the last exon of ggSRBI is marked in blue. 
 
Primer set ggSRBII-Fwd1/Rev1 was used for RT-PCR of laying hen liver total RNA, 
resulting in a 215bp PCR product (Fig. 3.4.3), which was then cloned into pCR 2.1-
Topo (Fig. 3.4.4) and sequenced (Fig. 3.4.5). 
 
Fig. 3.4.3 
RT-PCR of laying hen chicken liver 
total RNA, using primer set  
ggSRBII-Fwd1/Rev1. 
2,5…Liver total RNA 
3,4…Negative control 
 
 Fig. 3.4.4 EcoRI restriction enzyme 
digestion of RT-PCR product 
ggSRBII-Fwd1/Rev1 cloned into pCR 
2.1-Topo. 1,2,3,4…Clones 1-4 
 
 
mmSRBII         ATCTGCCAACTGCGCAGCCAGGGTCCTGAAGACACTATAAGCCCCCCAAACCTGATAGCT 1440 
rnSRBII         ATTTACCAACTGCGCAGCCAGGGCCCAGAAGACACCACGAGCCCCCCAAACCTGATAGCT 1440 
hsSRBII         ATCTGCCAAATCCGGAGCCAAGGTCCTGAGGACACCGTGAGCCAGCCAGGCCTGGCCGCT 1440 
btSRBII         ATCTACCAAATCCGGAGCCAAGGTTCCAAAGATGCCATCAGCCAGCCCTGTCTGGCCACT 1440 
                ** * **** * ** ***** **  *  * **  *    ****  **    ***    ** 
 
mmSRBII         TGGTCAGACCAGCCACCCAGTCCCTACACCCCGCTTCTTGAGGACTCTCTCAGCGGACAG 1500 
rnSRBII         TGGTCAGACCAGCCGCCCAGTCCCTACACCCCACTTCTCGAGGACTCTCTCAGCGGACAA 1500 
hsSRBII         GGGCCTGACCGGCCCCCCAGCCCCTACACCCCGCTTCTCCCGGACTCTCCCAGCGGACAG 1500 
btSRBII         CAGCCAGACCAACTTCCCAGCCCCTACACCCCGCTTCTTCAGGACTCGCTCCGTGGACAG 1500 
                  * * ****  *  ***** *********** *****   ****** * * * *****  
 
mmSRBII         CCCACCAGTGCCATGGCCTGA 1521 
rnSRBII         CCCGCCAGTGCCACGTCCTGA 1521 
hsSRBII         CCCCCCAGCCCCACAGCCTGA 1521 
btSRBII         CCCACCAGTCCCAAAGTCTGA 1521 
 
 
agagagtggatacattgatggctcagtcctatcgcagttttacaccaacctggtgctgatcccatcca 1309 
tcctagactacctgcagtacatcttcctcgggctcagcgtcccgctcatcatctcagctgcactcgtg 1377 
atgatgagtcagaagtcctccaaggagaagcacccacacgaccccaccacgcagagccccccacccca 1445 
gccctccgagaccacaccgctcctccaggacaccggcacacagagccaggacaccgccgaggcctga  1512 
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Fig. 3.4.5 Nucleotide alignment of ggSRBI and PCR product of primer set  
ggSRBII-Fwd1/Rev1 (marked in red). The last exon of ggSRBI is marked in blue. 
 
Surprisingly, primer set ggSRBII-Fwd1/Rev1 seemed to amplify ggSRBI, even 
though ggSRBII-Rev1 was derived from a homology domain of SRBII cDNA  
sequences of different species. For further investigation of this phenomenon, amino 
aicd sequence alignments of SRBI (Fig. 3.4.6) and SRBII (Fig. 3.4.7)  of different 
species, with ggSRBI, were done.  
Fig. 3.4.6 Amino acid sequence alignment of mouse, rat, human, rabbit, bovine, and 
chicken SRBI. A homology domain found in SRBI proteins of all species aligned,  
except ggSRBI, is marked in red. The beginning of the last exon of SRBI is marked in 
blue. 
 
 
ggSRBI                 GGGAAGATTCAGCCTGTGGTGATGCCGCTGCTGTGGTTTGCAGAGAGTGGATACATTGAT 1260 
ggSRBII-Fwd1/Rev1      ---------------------------------------------------------GAT 3 
                                                                                *** 
 
ggSRBI                 GGCTCAGTCCTATCGCAGTTTTACACCAACCTGGTGCTGATCCCATCCATCCTAGACTAC 1320 
ggSRBII-Fwd1/Rev1      GGCTCAGTCCTATCGCAGTTTTACACCAACCTGGTGCTGATCCCATCCATCCTAGACTAC 63 
                       ************************************************************ 
 
ggSRBI                 CTGCAGTACATCTTCCTCGGGCTCAGCGTCCCGCTCATCATCTCAGCTGCACTCGTGATG 1380 
ggSRBII-Fwd1/Rev1      CTGCAGTACATCTTCCTCGGGCTCAGCGTCCCGCTCATCATCTCAGCTGCACTCGTGATG 123 
                       ************************************************************ 
 
ggSRBI                 ATGAGTCAGAAGTCCTCCAAGGAGAAGCACCCACACGACCCCACCACGCAGAGCCCCCCA 1440 
ggSRBII-Fwd1/Rev1      ATGAGTCAGAAGTCCTCCAAGGAGAAGCACCCACACGACCCCACCACGCAGAGCCCCCCA 183 
                       ************************************************************ 
 
ggSRBI                 CCCCAGCCCTCCGAGACCACACCGCTCCTCCAGGACACCGGCACACAGAGCCAGGACACC 1500 
ggSRBII-Fwd1/Rev1      CCCCAGCCCTCCGAGACTACACCCCACTTCTG---------------------------- 215 
                       ***************** ***** * * **                               
 
ggSRBI                 GCCGAGGCCTGA 1512 
ggSRBII-Fwd1/Rev1                      ------------ 
 
mmSRBI          AMGGKPLSTFYTQLVLMPQVLHYAQYVLLGLGGLLLLVPIICQLRSQEKCFLFWSGSKKG 480 
rnSRBI          MMGGKTLNTFYTQLVLMPQVLHYAQYVLLGLGGLLLLVPIIYQLRSQEKCFLFWSGSKKG 480 
hsSRBI          AMEGETLHTFYTQLVLMPKVMHYAQYVLLALGCVLLLVPVICQIRSQEKCYLFWSSSKKG 480 
ocSRBI          AMEGETLSTFYTQLVLLPNVLQYAQYVLLALGCVLLLAPVIYQVRSQEKCYLFWSSSKKG 480 
btSRBI          AMEGETLETFYIQLVLMPKVLHYAQYVLLALGCVLLLIPIIYQIRSQEKCYLFWISFKKG 480 
ggSRBI          YIDGSVLSQFYTNLVLIPSILDYLQYIFLGLS-VPLIISAALVMMSQKSSKEKHPHDPTT 476 
                 : *. *  ** :***:*.::.* **::*.*. : *: .    : **:..        .  
 
mmSRBI          SQDKEAIQAYSESLMSPAAKGTVLQEAKL 509 
rnSRBI          SQDKEAMQAYSESLMSPAAKGTVLQEAKL 509 
hsSRBI          SKDKEAIQAYSESLMTSAPKGSVLQEAKL 509 
ocSRBI          SKDKEAAQAYSESLMTPDPKGTVLQEARL 509 
btSRBI          SKDKEAVQAYSEFLMTSAPKGTVLQEARL 509 
ggSRBI          QSPPPQPSETTPLLQDTGTQSQDTAEA-- 503 
                                                                         ..     .  :  *  . .:.    **   
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Fig. 3.4.7 Amino acid sequence alignment of mouse, rat, human, rabbit and bovine 
SRBII, and ggSRBI. A homology domain found in SRBII proteins of all species, but 
also in ggSRBI, is marked in red. The beginning of the last exon of SRBII is marked 
in blue. 
 
The homology domain found in the last exon of those other species and chicken, was 
then used to design a new reverse primer, called ggSRBII-Rev3 (Fig. 3.4.8). For  
introduction of mouse liver total RNA as a positive control, a new forward primer 
called ggSRBII-Fwd3 (Fig. 3.4.9), located in a homology domain of mouse and 
chicken SRBI, was designed.  Thus, this primer set was supposed to amplify 
mmSRBII and ggSRBII.  
Fig. 3.4.8 Nucleotide alignment of mouse, rat, human and bovine SRBII. Reverse 
primer ggSRBII-Rev3 is marked in red. The beginning of the last exon of SRBII is 
marked in blue. 
 
mmSRBII         AMGGKPLSTFYTQLVLMPQVLHYAQYVLLGLGGLLLLVPIICQLRSQGPEDTISPPNLIA 480 
rnSRBII         MMGGKTLNTFYTQLVLMPQVLHYAQYVLLGLGGLLLLVPIIYQLRSQGPEDTTSPPNLIA 480 
hsSRBII         AMEGETLHTFYTQLVLMPKVMHYAQYVLLALGCVLLLVPVICQIRSQGPEDTVSQPGLAA 480 
ocSRBII         AMEGETLSTFYTQLVLLPNVLQYAQYVLLALGCVLLLAPVIYQVRSQG-----RRQSLAA 475 
btSRBII         AMEGETLETFYIQLVLMPKVLHYAQYVLLALGCVLLLIPIIYQIRSQGSKDAISQPCLAT 480 
ggSRBI          YIDGSVLSQFYTNLVLIPSILDYLQYIFLGLSVPLIISAALVMMSQKSSKEKHPHDPTTQ 477 
                 : *. *  ** :***:*.::.* **::*.*.  *:: . :  : .:.             
 
mmSRBII         WSDQPPSPYTPLLEDSLSGQPTSAMA 506 
rnSRBII         WSDQPPSPYTPLLEDSLSGQPASATS 506 
hsSRBII         GPDRPPSPYTPLLPDSPSGQPPSPTA 506 
ocSRBII         GPEQPAGPHTPLLQDSPCGPPAGPTA 501 
btSRBII         QPDQLPSPYTPLLQDSLRGQPTSPKV 506 
ggSRBI          SPPPQPSETTPLLQDTGTQSQDTAEA 503 
                 .   ..  **** *:       .   
 
mmSRBII         ATCTGCCAACTGCGCAGCCAGGGTCCTGAAGACACTATAAGCCCCCCAAACCTGATAGCT 1440 
rnSRBII         ATTTACCAACTGCGCAGCCAGGGCCCAGAAGACACCACGAGCCCCCCAAACCTGATAGCT 1440 
hsSRBII         ATCTGCCAAATCCGGAGCCAAGGTCCTGAGGACACCGTGAGCCAGCCAGGCCTGGCCGCT 1440 
btSRBII         ATCTACCAAATCCGGAGCCAAGGTTCCAAAGATGCCATCAGCCAGCCCTGTCTGGCCACT 1440 
                ** * **** * ** ***** **  *  * **  *    ****  **    ***    ** 
 
mmSRBII         TGGTCAGACCAGCCACCCAGTCCCTACACCCCGCTTCTTGAGGACTCTCTCAGCGGACAG 1500 
rnSRBII         TGGTCAGACCAGCCGCCCAGTCCCTACACCCCACTTCTCGAGGACTCTCTCAGCGGACAA 1500 
hsSRBII         GGGCCTGACCGGCCCCCCAGCCCCTACACCCCGCTTCTCCCGGACTCTCCCAGCGGACAG 1500 
btSRBII         CAGCCAGACCAACTTCCCAGCCCCTACACCCCGCTTCTTCAGGACTCGCTCCGTGGACAG 1500 
                  * * ****  *  ***** *********** *****   ****** * * * *****  
 
mmSRBII         CCCACCAGTGCCATGGCCTGA 1521 
rnSRBII         CCCGCCAGTGCCACGTCCTGA 1521 
hsSRBII         CCCCCCAGCCCCACAGCCTGA 1521 
btSRBII         CCCACCAGTCCCAAAGTCTGA 1521 
                *** ****  ***    **** 
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Fig. 3.4.9 Nucleotide alignment of mouse and chicken SRBI. Forward primer 
ggSRBII-Fwd3 is marked in red. The beginning of the last exon of SRBI is marked in 
blue. 
Primer set ggSRBI was used for RT-PCR (Fig. 3.4.10) of laying hen and mouse liver 
total RNA, resulting in PCR products of 405bp length, which were then cloned into 
pCR 2.1-Topo (Fig. 3.4.11)  for sequencing (3.4.12).   
 
 
 
 
Fig. 3.4.10 RT-PCR of laying hen and mouse liver total RNA, using primer set 
ggSRBII-Fwd3/Rev 3. 
2,3,…Chicken total RNA 1 
5,6…Chicken total RNA 2 
8,9…Mouse total RNA 
11…Negative control 
1,4,7,10…Empty 
mmSRBI          TCTGCCCATGCCGAGAGTCTGGCATTCAGAATGTCAGCACCTGCAGGTTTGGTGCGCCTC 1018 
ggSRBI          TCTGTCCCTGCAGGCAATCCGGCATCCAGAACGTCAGCTCCTGCAGGCTGAATGCACCAA 1009 
                **** ** *** *  * ** ***** ***** ****** ******** *   *** **   
 
mmSRBI          TGTTTCTCTCCCACCCCCACTTTTACAACGCCGACCCTGTGTTGTCAGAAGCTGTTCTTG 1078 
ggSRBI          TGTTCATCTCCCACCCTCACTTCTACAATGCTGACCCAAGCCTGGTGGATGCTGTGGAAG 1069 
                ****  ********** ***** ***** ** *****     **   ** *****    * 
 
mmSRBI          GTCTGAACCCTAACCCAAAGGAGCATTCCTTGTTCCTAGACATCCATCCGGTCACTGGGA 1138 
ggSRBI          GCCTGCACCCCAGCAGGGAGGAGCACGCGCTCTTCCTCGATGTGCACCCGGTGACAGGCA 1129 
                * *** **** * *    *******  *  * ***** **  * ** ***** ** ** * 
 
mmSRBI          TCCCCATGAACTGTTCTGTGAAGATGCAGCTGAGCCTCTACATCAAATCTGTCAAGGGCA 1198 
ggSRBI          TCCCCATGAACTGCTCCATCAAGCTCCAGCTGAACCAGTACATGAAGCAGGTGTCTGGTA 1189 
                ************* **  * *** * ******* **  ***** **    **    ** * 
 
mmSRBI          TCGGGCAAACAGGGAAGATCGAGCCAGTAGTTCTGCCGTTGCTGTGGTTCGAACAGAGCG 1258 
ggSRBI          TCCTTCAAACAGGGAAGATTCAGCCTGTGGTGATGCCGCTGCTGTGGTTTGCAGAGAGTG 1249 
                **   **************  **** ** **  ***** ********** * * **** * 
 
mmSRBI          GAGCAATGGGTGGCAAGCCCCTGAGCACGTTCTACACGCAGCTGGTGCTGATGCCCCAGG 1318 
ggSRBI          GATACATTGATGGCTCAGTCCTATCGCAGTTTTACACCAACCTGGTGCTGATCCCATCCA 1309 
                **   ** * ****     ***      *** *****  * *********** **      
 
mmSRBI          TTCTTCACTACGCGCAGTATGTGCTGCTGGGGCTTGGAGGCCTCCTGTTGCTGGTGCCCA 1378 
ggSRBI          TCCTAGACTACCTGCAGTACATCTTCCTCGGGCTCAGCGTCCCGCTCAT-------CATC 1362 
                * **  *****  ******  *  * ** *****  * * **  **  *       *    
 
mmSRBI          TCATCTGCCAACTGCGCAGCCAGGAGAAATGCTTTTTGTTTTGGAGTGGTAGTAAAAAGG 1438 
ggSRBI          TCAGCTGC-ACTCGTGATGATGAGTCAGAAGTCCTCCA---AGGAGAAGCACCCACACGA 1418 
                *** **** *   * *  *    *  * * *   *       ****  * *   * * * 
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Transformation of chemically competent E.Coli worked for the chicken liver PCR 
product, but not for mouse. Even though PCR was succesful, not a single positive 
clone could be obtained from various transformation approaches.  
Fig. 3.4.11 
EcoRI restriction enzyme digestion of 
ggSRBII-Fwd3/Rev3 PCR product cloned 
into pCR 2.1-Topo.                                                                 
1,2,3,4,5,6…Clones 1-6 
 
Positive clone 2 was sequenced and a nucleotide alignment of ggSRBII-Fwd3/Rev3 
PCR product and ggSRBI was done. GgSRBII-Fwd3 was localized in a region  
identical for SRBI and SRBII, way upstream of the alternative exon, from nucleotide 
1010-1029. Therefore, if these primers amplified ggSRBII, 380 nucleotides of the  
derived DNA fragment should match SRBI perfectly.  
Fig. 3.4.12 Nucleotide alignment of ggSRBI and PCR product of primer set  
ggSRBI-Fwd3/Rev3 (marked in red). Position of ggSRBI-Fwd3 sequence in ggSRBI 
is marked in blue . 
 
                                                                                  
ggSRBII-Fwd3/Rev3      ---------------TGTTCATCTCCCACCCTCACCATGCCCACTAACCACATCCCTGTG 45 
ggSRBI-FL              CCACCGTATATGTCCCCAACATCGCTGGAGTTCTACAGCCCCGATGCCTGCAGATCCATG 840 
                                          **** *      **  **  ***  *  *  **   *  ** 
 
ggSRBII-Fwd3/Rev3      TCACATCTCCAC-AGTTCTTGAGCACCTCCAGGGACAGACACTCC-ACCACTCCCTGG-- 101 
ggSRBI-FL              ACACTGGTGTACGAGCAGTCGGGGAAATTCAAGGGTGTGCCCACCTATCGCTTTGTGGCA 900 
                        ***   *  ** **   * * * *  * ** **     * * ** * * **   ***   
 
ggSRBII-Fwd3/Rev3      --GCATACTGTC----CCAGTG-CATT-ATCACTCTTCTTGGGAAGAAATTTTTTCCTA- 152 
ggSRBI-FL              CCGAAAACTCTCTTTGCCAATGGCACAGATTATCCCCCCAACGAAGGCTTCTGTCCCTGC 960 
                         * * *** **    *** ** **   ** *  *  *    ****   * * * ***   
 
ggSRBII-Fwd3/Rev3      ----------ACATCTA--ACATGAACCTCTACTGGCACAACTCAAGGCCATT-GCCTTT 199 
ggSRBI-FL              AGGCAATCCGGCATCCAGAACGTCAGCTCCTGCAGGCTGAATGCACCAATGTTCATCTCC 1020 
                                  **** *  ** * * *  ** * ***  **  **      **   **   
 
ggSRBII-Fwd3/Rev3      CATCCTAATATACAGCATGAAAAATACATTACTATTGATTTTTTTTTACCAACATATCCC 259 
ggSRBI-FL              CACCCTCACTTCTACAATGCTGACCCAAGCCTGGTGGATGCTGTGGAAGGCCTGCACCCC 1080 
                       ** *** *  *  *  ***   *    *      * ***  * *   *       * *** 
 
ggSRBII-Fwd3/Rev3      AGTCTTTAAATTTCTGCACAGTT----GATTT--------TGAGAATCATCACT-TGGTG 306 
ggSRBI-FL              AGCAGGGAGGAGCACGCGCTCTTCCTCGATGTGCACCCGGTGACAGGCATCCCCATGAAC 1140 
                       **     *       ** *  **    *** *        *** *  **** *  **    
 
ggSRBII-Fwd3/Rev3      AGTTTTAGCTTG-TCTGTGTGAACAG---CAGCAGGCAGTTG-CTAGTTTGGTTCCTGAA 361 
ggSRBI-FL              TGCTCCATCAAGCTCCAGCTGAACCAGTACATGAAGCAGGTGTCTGGTATCCTTCAAACA 1200 
                        * *  * *  * **    *****     **  * **** ** ** ** *  ***    * 
 
ggSRBII-Fwd3/Rev3      ATGAAGAGTGCAGCTGACATGAAGCC--TACTCTGAGTCCCTGATG-------------- 405 
ggSRBI-FL              GGGAAGATTCAGCCTGTGGTGATGCCGCTGCTGTGGTTTGCAGAGAGTGGATACATTGAT 1260 
                         ***** *    ***   *** ***  * ** **  *  * **                 
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The DNA fragment derived from primer set ggSRBI-Fw3/Rev3 did not match SRBI, 
indicating unspecific amplification of DNA fragments.  
After those negative results so far, one last PCR approach was performed, using 
ggSRBII-Fwd 1.2/Rev3 as primer set (Fig. 3.4.13). GgSRBII-Fwd1.2 corresponded to 
the same position as ggSRBII-Fwd1, but its 3´end was extended for 3 nucleotides, so 
PCR conditions of the forward and reverse primer were more similar. The PCR  
product of this primer set therefore should be smaller, than that of  
ggSRBII-Fwd3/Rev3, increasing the possibility of successful PCR.  
Fig. 3.4.13 
RT-PCR of laying hen liver total RNA, using ggSRBII-
Fwd1.2/Rev3 as primer set. 
1…Laying hen 
2…Negative control 
3…Empty 
  
Though using different PCR programs, no product could be obtained, probably  
indicating problems in reverse primer binding to the homology domain, which the re-
verse primer was located to. PCR mediated amplification of SRBII also might  have 
failed, because that SRB isoform does not exist in chicken.  
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4 Discussion 
 
Human Scavenger Receptor Class B Type I (SRBI) has been identified as the first 
physiologically relevant HDL-binding receptor. Its main function is mediating selective 
lipid uptake. Due to its role in HDL metabolism and its expression in many different 
tissues and cell types, SRBI affects several physiological processes of great medical 
interest, such as atherosclerosis, female fertility, fetal development and others  
mentioned in the Introduction. Chicken is a well characterized and easy to  
manipulate model organism for lipid metabolism. Thus, this diploma work was  
performed to identify and characterize putative chicken SRBI (ggSRBI) and its possi-
bly existing isoform, SRBII. 
 
Chicken ENSEMBL database search revealed an mRNA sequence  
(GENSCAN00000043265) referred to as ggSRBI. According to this sequence,  
primers were designed and used for amplification of full-length ggSRBI cDNA from 
laying hen liver total RNA by RT-PCR. The resulting PCR product was then cloned 
into apCR 2.1-TOPO plasmid and sequenced. The amplified PCR product was 100% 
identical with the sequence derived from ENSEMBL database. The open reading 
frame coding for ggSRBI is of a length of 1512bp and is translated to a 503 amino 
acid polypeptide with a predicted molecular weight of ~56kDa. Human SRBI is  
heavily glycosylated and palmitoylated, and thus its apparent molecular weight is 
82kDa, significantly larger than the predicted size of 57kDa.. It is not yet known 
whether ggSRBI is similarly glycosylate.  
 
For further investigations of ggSRBI at the protein level, an anti-ggSRBI antibody was 
generated. A fragment of ggSRBI, from amino acids 42-276, was recombinantly  
expressed as HIS-tag, HSV-tag fusion protein of a predicted molecular weight of 
~31kDa in E.coli. Purification of the recombinant protein using Ni-NTA agarose was 
unfortunately unsuccessful. Once the recombinant protein had bound to the Ni-NTA 
agarose, it  did not dissociate again, even though several modified approaches were 
performed. Thus, the recombinant protein was seperated by performing  
polyacrylamide gel electrophoresis, visualized by Coomassie blue staining and  
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excised directly from the gel. A rabbit was immunized with the recombinant protein 
and the immune serum was tested for its ability to recognize ggSRBI.  
Western blots of laying hen liver total protein extracts were performed, using the  
rabbit serum as primary antibody and pre-immune serum from the same rabbit as 
negative control. First, different dilutions (1:100, 1:500, 1:1000) of immune serum in 
5%milk, TBST, 2mMCaCl2 (blocking solution) were tested. All 3 dilutions resulted in 
visualization of a band in laying hen liver total protein extracts of ~64kDa, and ac-
cording to the dilution of the immune serum the signal varied in intensity.  
Furthermore, this band was not obtained using pre-immune serum as primary  
antibody, thus indicating specific reactivity. The predicted molecular weight of 
ggSRBI is 56kDa as mentioned above, but if ggSRBI is glycosylated like human 
SRBI, the obtained 64kDa signal in Western blotting might correspond to ggSRBI. A 
dilution ratio of immune serum and blocking solution of 1:500 is quite useful, as a  
distinct signal could be obtained and anti-serum could be saved. Thus, this dilution 
was used for further Western blots using the antiserum as primary antibody.   
Denaturation of proteins during SDS-PAGE under reducing conditions  may influence 
the binding ability of the antibody used for its detection. Thus, Western blots of laying 
hen liver total protein extracts were performed under reducing and non-reducing 
conditions. Under reducing conditions, a signal was obtained similar to that described 
above, whereas under non-reducing condition the 64kDa-band almost disappeared. 
Instead, other bands of 50kDa, 90kDa, 95kDa and higher became visible. As human 
SRBI is known to dimerize, this could be true for ggSRBI as well, and thus the 90kDa 
and 95kDa signals may be due to to such homodimerization. As mentioned, the 50 
kDa signal was the most intensive one, but this band was also obtained using pre-
immune serum, indicating unspecific antibody binding. Most probably the antiserum 
binds non-reduced ggSRBI less efficiently, maybe due to epitope inaccessibility.  
For further investigation of ggSRBI binding specificity of the immune serum,  
competition assays were performed of laying hen total protein extracts byincluding 
the recombinantly expressed protein used for immunization as competitor for the  
antigen-antibody interaction.. Immune serum was supposed to bind to the added  
recombinant protein, thereby limiting ggSRBI specific antibodies in the serum avail-
able for binding to the ggSRB in the protein extract. Surprisingly, addition of the  
competitor increased the intensity of the 64kDa signal obtained, instead of  
decreasing it as supposed. Dimerization of ggSRBI bound to the nitrocellulose  
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membrane with the recombinantly expressed protein added to the incubation mixture 
might be the cause for this phenomenon. As mentioned above, human SRBI is 
known to dimerize, therefore dimerization of ggSRBI and the recombinantly ex-
pressed fragment of ggSRBI is quite possible, and thus it can be concluded that ithe 
antibodies indeed binds to ggSRBI in specific manner. 
Binding specifity of rb-anti-ggSRBI was tested also in other species. Therefore a 
Western blot of liver total protein extracts from laying hen, mouse and quail was  
performed using the antiserum as source of primary antibodies. Distinct signals were 
obtained for all three species: the usual 64kDa signal in laying hen, a 61kDa signal in 
mouse, and a 67kDa signal in quail. No other signals of significant intensity were  
obtained. , again suggesting specific binding of rb-anti-ggSRBI to quail and mouse 
SRBI. This antiserum therefore might be a useful tool for further investigations of 
SRBI in species other than chicken as well.  
 
SRBI is expressed in many different cell types and tissues, and at different levels. 
Gene expression of SRBI was investigated in this diploma work, performing Northern 
blot analysis of total RNA isolated from different tissues. For optimization of the 
Northern blot, only tissues known to express SRBI at high levels in other species 
were used, namely, liver and adrenals. GgSRBI fragments from nucleotide 124-828 
and 93-1422, as well as an ApolipoproteinAV probe kindly donated by Dr. Andrea 
Dichlberger, were used as radiolabelled probes. ApoAV mRNA, present in liver  
extracts, served as positive control. Northern blotting of liver and adrenal total RNA 
extracts was performed and probes were added, but the only signal obtained was 
from the ApoAV-probe in liver total RNA extract. A double band at 2.3kb and ~1.4kb 
was obtained, consistent with former findings of Dr. Andrea Dichlberger, indicating 
functional Northern blotting. According to the ENSEMBL database, ggSRBI mRNA 
consists of 1821b. Yet, no signal was obtained from either of the two ggSRBI probes 
used. GgSRBI probe 93-1422 even seemed to stick to the markers, a phenomenon 
not observed with the ggSRBI probe 124-828. Lowering the incubation temperature 
for ggSRBI probe 124-828 to make Northern blot conditions less stringent, did also 
not result in a ggSRBI signal. Probes were labelled according to the manufacturer’s 
protocol and fractioned with NICK columns. Radioacitve nucleotide incorporation was 
verified using a Geiger counter. Additionally, the positive control was positive,  
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indicating succesful Northern blotting. Thus, the ggSRBI fragments used or the 
preparation of the mRNA may have been the cause of the problem. Probably,  
secondary structures within either the probes or the mRNA impaired probe binding. 
Possibly,  real-time PCR techniques may solve the problems and allow investigation 
of ggSRBI mRNA levels. 
 
Alternatively spliced variants of SRBI are known to exist in humans and many other 
species. So-called SRBII has been described for human, cow, pig, rat , and mouse. 
Thus, an isoform-search was performed using RT-PCR to amplify ggSRBII from  
laying hen liver total RNA,. In all species studied to date, SRBI and SRBII only differ 
in their last exon. This last exon codes for the C-terminal cytoplasmatic domain of the 
protein, which is thought to mediate cellular responses to receptor binding. Due to 
that essential function, a conserved region, within the last exon, typical for one or the 
other isoform was expected to exist. Thus, mouse, human, cow, and rat SRBII cDNA 
nucleotide sequences were aligned and searched for a highly conserved region in 
the last alternative exon of SRBII. Forward PCR primers for were set upstream, 
where SRBI and SRBII nucleotide sequences are identical, and reverse primers were 
set in the conserved region within the last SRBII exon. The PCR product then was 
cloned into a pCR 2.1-TOPO vector, amplified in E.coli and sequenced. Surprisingly, 
the amplified part was 100% identical with the putative ggSRBI, even though the  
reverse primer was designed according to SRBII sequences of other species. Thus, 
mouse, rat, human, cow, and rabbit SRBI and SRBII protein amino acid sequences 
were aligned and compared to ggSRBI. SRBI proteins from all species mentioned 
share an SESL motif within their last exon, and SRBII proteins of all species  
mentioned share a TPLL motif within their last exon. In contrast, the obtained SRB 
from chicken contained the otherwise typical SRBII motif TPLL, indicating that the 
protein referred to as ggSRBI, should in fact be considered to be ggSRBII. 
Therefore, I designed new primers targetted to the SRBI-typical SESL motif found 
within the last exon and a region upstream of the last exon, conserved in ggSRBI and 
mmSRBI. This new primer set was supposed to amplify mmSRBI as positive control, 
and potentially also ggSRBI (and not the protein named ggSRBI so far). PCR  
products of ~400bp length were obtained by RT-PCR of laying hen and mouse liver 
total RNA. PCR products were clonend into pCR 2.1-TOPO and transformed into 
E.coli, but only colonies of bacteria containing the fragment amplified from the 
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chicken transcript s could be obtained. Even though PCR of mouse liver total RNA 
was repeated, it was not possible to obtain any transformed bacterial cells. Since the 
forward primer for the PCR was set within the area shared by SRBI and SRBII, if 
amplification of the potentially new ggSRBI was succesfull, 380 nucleotides were  
expected to be identical with the mRNA sequence referred to as “ggSRBI” so far. 
Yet, sequence analysis of the amplified fragment revealed no sequence homology 
between the fragment and ggSRBI sequence at all. Thus, in this diploma work it was 
not possible to identify a second alternatively spliced isoform of the protein referred 
to as ggSRBI in this Thesis.  
Taken together, these findings strongly suggest that, based on the presence of the 
otherwise typical SRBII-motif TPLL found in the chicken sequence, that the  
characterized cDNA is in fact encoding chicken scavenger receptor class B type II 
(ggSRBII), and not ggSRBI. Future searches on SRB isoforms - in chicken should 
focus on SRBI or on other not yet known types of alternative splice variants.  
Following the suggestion of renaming ggSRBI to ggSRBII, ggSRBII would share the 
typical TPLL motif found in SRBII of other species. Therefore it seems likely that a 
type I isoform in chicken should contain the SESL motif of SRBI found in other  
species. Still, it was not possible to amplify from total RNA  an isoform containing the 
homology region of SRBI proteins of other species- Possibly, primers set in the  
homology region could not bind due to steric reasons like secondary structures, or a 
type-I isoform of SRB in chicken actually does not exist. It should be noted that the 
Western blots showed only one band, despite the fact that the antibody raised should 
react with the hypothetical SRBI as well; however, if the chicken SRBs were splice 
variants analogous to those in mammals, their size difference might be too small to 
resolve two bands. Future studies will address this point as well.    
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6 Abstract 
 
Besides its housekeeping functions in all mammalian cells, cholesterol contributes to 
different biological functions like bile acid-, vitamin D- or steroid hormone synthesis. 
Thus, multiple pathways have evolved to ensure full supply of animal cells with  
cholesterol, involving different lipoproteins and cell surface receptors.  
Human SRBI, initially identified in 1994 by Endemann, Acton, Krieger and  
colleagues, was the first HDL receptor of physiological relevance to be found. SRBI 
is a member of a family of structurally related proteins, called the CD36 superfamily. 
It is anchored in the cellular plasma membrane and found in cells of a wide variety of 
tissues, where expression levels are highest in liver and steroidogenic tissues. The 
main function of SRBI is mediating bi-directional selective lipid transfer, mainly in the 
form of cholesteryl esters, from HDL particles to and from cells. Hepatic  
overexpression of SRBI in mice leads to decreased plasma HDL cholesterol concen-
tration, as well as to an increase in hepatic bile cholesterol concentration, whereas 
SRBI knock-out mice show a 2-2.5-foldelevated total plasma cholesterol  
concentration, caused by an increase in large HDL particles heterogeneous in size, 
which are abnormally enriched in apoprotein E. These findings indicated that SRBI is 
important for cellular cholesterol uptake from HDL particles, thereby ensuring  
sufficient cholesterol supply of steroigenic tissues, as well as reverse cholesterol 
transport from extrahepatic tissues to the liver, thus mediating secrection of excess 
cholesterol into bile. Due to the reported physiological functions, SRBI is supposed to 
be involved in different pathophysiological processes like atherosclerosis or female 
infertility. Thus, SRBI is a promising target for investigation of the molecular  
mechanisms underlying these pathological conditions.  
Most of the studies concerning SRBI were performed using rodents as model  
organisms. Yet, as chicken is a well characterized and easy to manipulate model  
organism for studies on lipid metabolism, this diploma work was performed to identify 
and characterize possibly existing chicken SRBI (ggSRBI). Therefore, ggSRBI was 
cloned from laying hen chicken liver total RNA extracts and an antibody was raised 
against it, using a recombinantly expressed fragment of ggSRBI for immunization of 
a rabbit. Performing Western blot experiments, resulting in a specific ~64kDa signal, 
binding specifity of the antibody was proven. Furthermore, gene expression of SRBI 
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in different tissues was investigated, performing Northern blotting of laying hen total 
tissue RNA extracts. However, although using different radiolabelled probes and  
experimental conditions, no ggSRBI mRNA signal could be obtained. An isoform 
search for SRBI was performed, as in other species like human, mouse or rat, an 
alternatively spliced isoform of SRBI, called SRBII, had been found. Therefore  
RT-PCR of laying hen liver total RNA using forward primers set in a region identical 
for both isoforms, and reverse primers set in a conserved homology region of known 
SRBII sequences of other species, was performed. Although using different PCR 
programs and primer sets, no isoform could be obtained. Yet, it could be shown that 
the mRNA sequence referred to as SRBI, derived from ENSEMBL chicken database, 
surprisingly contained a homology motif, which was found in SRBII-, but not in  
SRBI-sequences of other species. This indicates that the cDNA characterized here in 
fact is encoding ggSRBII rather than ggSRBI.  
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7 Zusammenfassung 
 
Neben seiner Haushaltsfunktionen in allen Säugetierzellen, trägt Cholesterin zu  
verschiedenen biologischen Funktionen bei, wie zum Beispiel zu  
Gallensäureproduktion, Vitamin D- und Steroidhormon- Synthese. Verschiedene 
Wege zur Gewährleistung der vollen Versorgung der tierischen Zellen mit  
Cholesterin sind evolutionär entstanden, inklusive verschiedener Lipoproteine und 
Zelloberflächenrezeptoren. Humanes SRBI, 1994 erstmals von Endemann, Acton, 
Krieger und Kollegen identifiziert, war der erste physiologisch relevante HDL  
Rezeptor der gefunden wurde. SRBI ist Mitglied einer Familie von  
strukturverwandten Proteinen, der CD 36 Superfamilie. Es ist in der zellulären  
Plasmamembran verankert und in einer großen Anzahl an verschiedenen Geweben 
gefunden worden, obgleich der Expressionslevel in Leber und steroidogenen  
Geweben am höchsten ist. Die Hauptfunktion von SRBI ist die Vermittelung von 
bidirektionalem selektivem Lipidtransfer, hauptsächlich in Form von  
Cholesterylestern, von HDL Partikeln zu Zellen und umgekehrt. Hepatische  
Überexpression von SRBI in Mäusen führt zu einer Senkung der Plasma  
HDL-Cholesterinkonzentration, während SRBI knockout-Mäuse einen 2-2,5 fachen 
Anstieg der totalen Plasmacholesterinkonzentration zeigen, verursacht durch einen 
Anstieg an großen HDL Partikeln, welche heterogen in ihrem Umfang und  
außergewöhnlich mit apolipoprotein E angereichert sind. Diese Ergebnisse deuten 
darauf hin, dass SRBI für die zelluläre Aufnahme von Cholesterin wichtig ist,  
wodurch die ausreichende Versorgung von steroidogenen Geweben mit Cholesterol 
gewährleistet wird, sowie den entgegengesetzten Cholesteroltransport von  
extrahepatischen Geweben zur Leber, wodurch die Sekretion von überschüssigem 
Cholesterin in die Gallensäure vermittelt wird. Aufgrund der festgestellten  
physiologischen Funktionen wird vermutet, dass SRBI in verschiedene  
pathophyiologische Prozesse, wie Atherosklerose und weibliche Unfruchtbarkeit,  
involviert ist. Daher ist SRBI ein vielversprechendes Ziel zur Untersuchung der  
molekularen Mechanismen, die diesen pathologischen Bedingungen zu Grunde lie-
gen. Die meisten Studien betreffend SRBI wurden in Nagetieren als Modellorganis-
men durchgeführt. Da jedoch das Haushuhn ein gut charakterisierter und leicht zu 
manipulierender Modellorganismus für das Studium des Fettstoffwechsels ist, wurde 
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diese Diplomarbeit durchgeführt, um möglicherweise existierendes Hühner SRBI 
(ggSRBI) zu identifizieren und zu charakterisieren. Dafür wurde ggSRBI aus Total 
RNA-Extrakten einer Legehennenleber kloniert und ein Antikörper dagegen erzeugt, 
indem ein rekombinant exprimiertes Fragment von ggSRBI verwendet wurde, um ein 
Kaninchen zu immunisieren. Western blot Experimente, welche ein ~64kDa Signal 
ergaben, wurden durchgeführt, um die Bindungsspezifität des Antikörpers zu  
beweisen. Des weiteren wurde die Genexpression von ggSRBI in verschiedenen 
Geweben mittels Northern blotting von Total RNA-Extrakten einer Legehennenleber 
untersucht. Aber obwohl verschiedene radioaktive Sonden und unterschiedliche  
experimentelle Bedingungen verwendet wurden, konnte kein mRNA Signal erhalten 
werden. Eine Isoformsuche für ggSRBI wurde durchgeführt, da in anderen Spezies 
wie Mensch, Maus und Ratte eine alternativ gespleißte Isoform von SRBI namens 
SRBII gefunden wurde. Dafür wurden RT-PCRs mit RNA aus Legehennenleber 
durchgeführt, unter Verwendung von Vorwärts-Primern, die für eine Region in der die 
beiden Isoformen identisch sind bestimmt waren, und mit Rückwärts-Primern,  
korrespondierend mit einer konservierten homologen Region der bekannten SRBII 
Sequenzen anderer Spezies. Obwohl verschiedene PCR Programme und Primer 
verwendet wurden, konnte keine Isoform entdeckt werden. Es war jedoch möglich zu 
zeigen, dass die mRNA Sequenz, die bisher als SRBI bezeichnet wurde, und von 
ENSEMBL stammte, überraschenderweise ein homologes Motiv beinhaltete,  
welches zwar in SRBII, aber nicht in SRBI Sequenzen von anderen Spezies  
vorkommt. Dies deutet darauf hin, dass die cDNA, die in dieser Diplomarbeit  
charakterisiert wurde, tatsächlich für ggSRBII und nicht für ggSRBI kodiert. 
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